Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Influenza, Human | 113 | 2022 | 329 | 11.770 |
Why?
|
Genome-Wide Association Study | 131 | 2024 | 1611 | 6.040 |
Why?
|
Genetic Predisposition to Disease | 130 | 2024 | 2267 | 5.980 |
Why?
|
Influenza A virus | 82 | 2020 | 169 | 5.960 |
Why?
|
Polymorphism, Single Nucleotide | 140 | 2024 | 2350 | 5.850 |
Why?
|
Influenza Vaccines | 57 | 2022 | 142 | 5.640 |
Why?
|
Diabetes Mellitus, Type 2 | 85 | 2023 | 1372 | 3.820 |
Why?
|
Quantitative Trait Loci | 36 | 2021 | 576 | 3.580 |
Why?
|
Genetic Linkage | 72 | 2015 | 623 | 3.200 |
Why?
|
Genetic Variation | 66 | 2023 | 1349 | 3.030 |
Why?
|
Influenza A Virus, H1N1 Subtype | 33 | 2016 | 102 | 2.920 |
Why?
|
Influenza A Virus, H5N1 Subtype | 34 | 2017 | 63 | 2.840 |
Why?
|
Chromosome Mapping | 65 | 2021 | 1074 | 2.670 |
Why?
|
Humans | 561 | 2024 | 86281 | 2.660 |
Why?
|
Phenotype | 78 | 2024 | 2375 | 2.640 |
Why?
|
Genome, Human | 41 | 2024 | 756 | 2.610 |
Why?
|
Genotype | 88 | 2023 | 1850 | 2.420 |
Why?
|
Pharmacogenetics | 23 | 2022 | 434 | 2.400 |
Why?
|
Biological Specimen Banks | 6 | 2022 | 64 | 2.330 |
Why?
|
Influenza A Virus, H3N2 Subtype | 34 | 2017 | 80 | 2.320 |
Why?
|
Transcriptome | 16 | 2022 | 574 | 2.260 |
Why?
|
Models, Genetic | 42 | 2021 | 926 | 2.000 |
Why?
|
Calpain | 20 | 2006 | 111 | 1.920 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 34 | 2016 | 70 | 1.880 |
Why?
|
Gene Expression Regulation | 26 | 2021 | 1917 | 1.870 |
Why?
|
Alleles | 47 | 2021 | 1127 | 1.770 |
Why?
|
Quantitative Trait, Heritable | 14 | 2019 | 124 | 1.740 |
Why?
|
Computational Biology | 22 | 2022 | 528 | 1.720 |
Why?
|
Influenza in Birds | 16 | 2014 | 31 | 1.720 |
Why?
|
Global Health | 11 | 2022 | 193 | 1.690 |
Why?
|
Electronic Health Records | 15 | 2023 | 319 | 1.680 |
Why?
|
Disease Outbreaks | 31 | 2013 | 154 | 1.640 |
Why?
|
Pandemics | 9 | 2022 | 739 | 1.590 |
Why?
|
Databases, Genetic | 18 | 2021 | 259 | 1.570 |
Why?
|
Genetic Association Studies | 11 | 2020 | 294 | 1.560 |
Why?
|
Population Surveillance | 9 | 2022 | 219 | 1.500 |
Why?
|
Software | 19 | 2024 | 650 | 1.480 |
Why?
|
Polymorphism, Genetic | 42 | 2021 | 819 | 1.480 |
Why?
|
Gene Expression Profiling | 24 | 2021 | 1381 | 1.330 |
Why?
|
Linkage Disequilibrium | 32 | 2021 | 473 | 1.320 |
Why?
|
Alzheimer Disease | 10 | 2023 | 470 | 1.270 |
Why?
|
Stuttering | 10 | 2006 | 22 | 1.250 |
Why?
|
Gene Frequency | 40 | 2021 | 676 | 1.240 |
Why?
|
Neuraminidase | 21 | 2017 | 45 | 1.240 |
Why?
|
Female | 222 | 2024 | 44405 | 1.230 |
Why?
|
Orthomyxoviridae | 8 | 2019 | 37 | 1.210 |
Why?
|
Genomics | 18 | 2023 | 710 | 1.200 |
Why?
|
Asthma | 17 | 2022 | 947 | 1.190 |
Why?
|
Epidemiological Monitoring | 2 | 2018 | 39 | 1.160 |
Why?
|
DNA Copy Number Variations | 8 | 2021 | 171 | 1.160 |
Why?
|
Tourette Syndrome | 8 | 2021 | 25 | 1.130 |
Why?
|
Data Interpretation, Statistical | 10 | 2021 | 297 | 1.120 |
Why?
|
Male | 195 | 2024 | 40860 | 1.120 |
Why?
|
Gene Expression | 14 | 2023 | 1281 | 1.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 13 | 2011 | 689 | 1.090 |
Why?
|
Pharmacogenomic Variants | 5 | 2021 | 41 | 1.090 |
Why?
|
Genetics, Medical | 3 | 2024 | 52 | 1.050 |
Why?
|
Adult | 145 | 2023 | 25577 | 1.050 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 6 | 2021 | 199 | 1.050 |
Why?
|
World Health Organization | 7 | 2019 | 103 | 1.030 |
Why?
|
Insulin | 22 | 2017 | 1159 | 1.010 |
Why?
|
Child | 85 | 2022 | 6913 | 0.990 |
Why?
|
Multifactorial Inheritance | 12 | 2022 | 158 | 0.990 |
Why?
|
Disease | 8 | 2021 | 90 | 0.990 |
Why?
|
Diabetes Mellitus, Type 1 | 14 | 2021 | 566 | 0.960 |
Why?
|
Pedigree | 47 | 2017 | 966 | 0.960 |
Why?
|
Awards and Prizes | 1 | 2024 | 36 | 0.950 |
Why?
|
Breast Neoplasms | 16 | 2020 | 2881 | 0.940 |
Why?
|
Cytochrome P-450 CYP2D6 | 5 | 2014 | 52 | 0.930 |
Why?
|
Case-Control Studies | 41 | 2021 | 1801 | 0.920 |
Why?
|
Antigens, Viral | 16 | 2017 | 143 | 0.910 |
Why?
|
Nerve Tissue Proteins | 10 | 2017 | 503 | 0.900 |
Why?
|
Virus Replication | 18 | 2016 | 319 | 0.870 |
Why?
|
Gene Dosage | 4 | 2011 | 207 | 0.870 |
Why?
|
Antiviral Agents | 20 | 2014 | 508 | 0.870 |
Why?
|
Antineoplastic Agents | 16 | 2022 | 2351 | 0.860 |
Why?
|
Influenza B virus | 14 | 2015 | 29 | 0.840 |
Why?
|
Epithelial Cells | 6 | 2021 | 662 | 0.830 |
Why?
|
Viral Vaccines | 4 | 2021 | 43 | 0.830 |
Why?
|
Algorithms | 17 | 2023 | 1828 | 0.830 |
Why?
|
Child, Preschool | 56 | 2021 | 3608 | 0.790 |
Why?
|
Genes, Viral | 23 | 2009 | 116 | 0.790 |
Why?
|
Haplotypes | 32 | 2019 | 642 | 0.790 |
Why?
|
Risk Factors | 47 | 2024 | 5397 | 0.780 |
Why?
|
Influenza A Virus, H7N9 Subtype | 3 | 2015 | 3 | 0.780 |
Why?
|
Azathioprine | 4 | 2022 | 125 | 0.780 |
Why?
|
Kidney Tubules | 1 | 2021 | 94 | 0.780 |
Why?
|
United States | 49 | 2024 | 6637 | 0.760 |
Why?
|
Orthomyxoviridae Infections | 15 | 2016 | 46 | 0.760 |
Why?
|
Antibodies, Viral | 21 | 2021 | 293 | 0.750 |
Why?
|
Reassortant Viruses | 12 | 2015 | 23 | 0.750 |
Why?
|
Autistic Disorder | 9 | 2021 | 147 | 0.750 |
Why?
|
Stress, Mechanical | 1 | 2021 | 248 | 0.750 |
Why?
|
Genetic Testing | 13 | 2023 | 535 | 0.750 |
Why?
|
Molecular Sequence Data | 53 | 2014 | 3029 | 0.740 |
Why?
|
Mexican Americans | 14 | 2017 | 63 | 0.740 |
Why?
|
Animals | 97 | 2023 | 26518 | 0.740 |
Why?
|
Communicable Disease Control | 2 | 2018 | 51 | 0.740 |
Why?
|
Lod Score | 17 | 2007 | 152 | 0.740 |
Why?
|
Genetic Loci | 7 | 2023 | 250 | 0.740 |
Why?
|
Adolescent | 74 | 2021 | 8968 | 0.720 |
Why?
|
Chromosomes, Human, Pair 15 | 7 | 2010 | 63 | 0.720 |
Why?
|
Cisplatin | 10 | 2022 | 612 | 0.700 |
Why?
|
Hirschsprung Disease | 1 | 2019 | 11 | 0.700 |
Why?
|
Receptors, Kainic Acid | 1 | 2019 | 13 | 0.700 |
Why?
|
Genetic Markers | 33 | 2021 | 476 | 0.700 |
Why?
|
Cystic Fibrosis | 1 | 2020 | 112 | 0.700 |
Why?
|
Middle Aged | 100 | 2021 | 24957 | 0.690 |
Why?
|
Alternative Splicing | 5 | 2016 | 201 | 0.690 |
Why?
|
Laboratories | 1 | 2019 | 43 | 0.690 |
Why?
|
Probability | 5 | 2021 | 355 | 0.680 |
Why?
|
Models, Biological | 9 | 2021 | 1748 | 0.680 |
Why?
|
Hearing Loss | 4 | 2022 | 56 | 0.670 |
Why?
|
Eye Diseases | 1 | 2019 | 53 | 0.670 |
Why?
|
Antigenic Variation | 9 | 2016 | 26 | 0.660 |
Why?
|
Seasons | 14 | 2016 | 223 | 0.660 |
Why?
|
Tamoxifen | 3 | 2014 | 167 | 0.650 |
Why?
|
Genetic Diseases, Inborn | 7 | 2021 | 101 | 0.650 |
Why?
|
Mental Disorders | 5 | 2022 | 371 | 0.650 |
Why?
|
Human Genetics | 1 | 2018 | 6 | 0.640 |
Why?
|
Hemagglutinins, Viral | 12 | 2000 | 38 | 0.640 |
Why?
|
Vascular Diseases | 1 | 2019 | 119 | 0.640 |
Why?
|
Embryo, Nonmammalian | 1 | 2019 | 192 | 0.640 |
Why?
|
Women | 1 | 2018 | 25 | 0.630 |
Why?
|
Leukocytes | 5 | 2023 | 202 | 0.630 |
Why?
|
Cognitive Dysfunction | 4 | 2022 | 132 | 0.630 |
Why?
|
Influenza A Virus, H2N2 Subtype | 6 | 2014 | 10 | 0.630 |
Why?
|
Viral Proteins | 10 | 2016 | 300 | 0.630 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2014 | 589 | 0.630 |
Why?
|
Founder Effect | 7 | 2001 | 104 | 0.620 |
Why?
|
Polymorphism, Restriction Fragment Length | 21 | 2005 | 147 | 0.620 |
Why?
|
Knowledge | 1 | 2017 | 29 | 0.620 |
Why?
|
Organizational Innovation | 1 | 2017 | 41 | 0.620 |
Why?
|
Cultural Diversity | 1 | 2018 | 51 | 0.620 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2023 | 206 | 0.620 |
Why?
|
Psychiatry | 2 | 2008 | 78 | 0.610 |
Why?
|
Infant | 41 | 2021 | 3036 | 0.610 |
Why?
|
Cell Line | 32 | 2016 | 2466 | 0.600 |
Why?
|
Obsessive-Compulsive Disorder | 8 | 2014 | 157 | 0.600 |
Why?
|
Obesity | 14 | 2023 | 962 | 0.590 |
Why?
|
Cardiovascular Diseases | 5 | 2021 | 826 | 0.590 |
Why?
|
Vaccination | 16 | 2017 | 253 | 0.580 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 2 | 2014 | 5 | 0.570 |
Why?
|
Base Sequence | 38 | 2011 | 2329 | 0.570 |
Why?
|
Peripheral Nervous System Diseases | 4 | 2022 | 85 | 0.560 |
Why?
|
Mutation | 30 | 2020 | 3952 | 0.560 |
Why?
|
Chromosomes, Human, Pair 3 | 3 | 2016 | 54 | 0.560 |
Why?
|
Biomarkers | 6 | 2021 | 1709 | 0.560 |
Why?
|
Vaccines, Attenuated | 14 | 2014 | 51 | 0.550 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 1168 | 0.550 |
Why?
|
Databases, Factual | 3 | 2022 | 808 | 0.540 |
Why?
|
MicroRNAs | 8 | 2018 | 534 | 0.540 |
Why?
|
United Kingdom | 8 | 2021 | 164 | 0.530 |
Why?
|
Mixed Function Oxygenases | 3 | 2014 | 68 | 0.530 |
Why?
|
Aged | 66 | 2023 | 18353 | 0.530 |
Why?
|
Blood Glucose | 11 | 2017 | 873 | 0.520 |
Why?
|
Zoonoses | 2 | 2014 | 26 | 0.520 |
Why?
|
Neoplasms | 10 | 2022 | 2889 | 0.520 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2021 | 455 | 0.520 |
Why?
|
Depressive Disorder, Major | 3 | 2022 | 158 | 0.510 |
Why?
|
Drug Resistance, Viral | 9 | 2014 | 51 | 0.510 |
Why?
|
Methyltransferases | 4 | 2022 | 182 | 0.510 |
Why?
|
Warfarin | 3 | 2013 | 103 | 0.510 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 44 | 0.500 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2021 | 1196 | 0.500 |
Why?
|
Drug Discovery | 2 | 2012 | 103 | 0.500 |
Why?
|
Polycystic Ovary Syndrome | 7 | 2009 | 202 | 0.500 |
Why?
|
Biomarkers, Tumor | 6 | 2021 | 1461 | 0.490 |
Why?
|
Chromosomes, Human, Pair 16 | 5 | 2021 | 79 | 0.490 |
Why?
|
Chromosomes, Human, Pair 13 | 3 | 2015 | 51 | 0.490 |
Why?
|
Gene Regulatory Networks | 6 | 2020 | 291 | 0.490 |
Why?
|
Epistasis, Genetic | 4 | 2010 | 86 | 0.480 |
Why?
|
Ferrets | 18 | 2016 | 47 | 0.480 |
Why?
|
Ice Cover | 1 | 2013 | 2 | 0.480 |
Why?
|
Exons | 6 | 2012 | 450 | 0.480 |
Why?
|
Apolipoprotein L1 | 2 | 2023 | 7 | 0.470 |
Why?
|
Testicular Neoplasms | 3 | 2022 | 104 | 0.470 |
Why?
|
Systems Biology | 2 | 2014 | 42 | 0.470 |
Why?
|
Genome, Viral | 9 | 2012 | 74 | 0.470 |
Why?
|
Diabetes Complications | 4 | 2012 | 206 | 0.470 |
Why?
|
Estrogen Antagonists | 1 | 2013 | 47 | 0.470 |
Why?
|
Glucuronosyltransferase | 4 | 2021 | 184 | 0.470 |
Why?
|
Chromosomes, Human, Pair 2 | 11 | 2010 | 85 | 0.470 |
Why?
|
Schizophrenia | 6 | 2021 | 464 | 0.470 |
Why?
|
Information Dissemination | 3 | 2017 | 103 | 0.460 |
Why?
|
Climate Change | 1 | 2013 | 42 | 0.460 |
Why?
|
Exome | 7 | 2019 | 127 | 0.460 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2012 | 369 | 0.450 |
Why?
|
Polymerase Chain Reaction | 13 | 2011 | 927 | 0.450 |
Why?
|
History, 20th Century | 5 | 2018 | 312 | 0.450 |
Why?
|
Attitude of Health Personnel | 2 | 2008 | 636 | 0.450 |
Why?
|
Transcription Factors | 13 | 2018 | 1555 | 0.450 |
Why?
|
Organ Specificity | 7 | 2021 | 257 | 0.440 |
Why?
|
Cohort Studies | 23 | 2022 | 2759 | 0.440 |
Why?
|
RNA, Viral | 19 | 2009 | 327 | 0.440 |
Why?
|
Sequence Analysis, DNA | 14 | 2021 | 853 | 0.440 |
Why?
|
Delivery of Health Care | 1 | 2017 | 423 | 0.440 |
Why?
|
Molecular Epidemiology | 4 | 2011 | 53 | 0.440 |
Why?
|
Amino Acid Sequence | 28 | 2013 | 2062 | 0.440 |
Why?
|
Genetics, Population | 8 | 2017 | 394 | 0.430 |
Why?
|
Phylogeny | 26 | 2015 | 1136 | 0.430 |
Why?
|
Endoplasmic Reticulum | 1 | 2014 | 250 | 0.430 |
Why?
|
Sex Factors | 11 | 2020 | 1053 | 0.430 |
Why?
|
Privacy | 1 | 2012 | 20 | 0.430 |
Why?
|
Reproducibility of Results | 14 | 2020 | 2699 | 0.430 |
Why?
|
Disease Susceptibility | 12 | 2021 | 192 | 0.430 |
Why?
|
Anticoagulants | 3 | 2013 | 404 | 0.420 |
Why?
|
RNA-Binding Proteins | 6 | 2017 | 244 | 0.420 |
Why?
|
Brain | 8 | 2023 | 2211 | 0.420 |
Why?
|
Pyrophosphatases | 2 | 2022 | 16 | 0.420 |
Why?
|
Hypersensitivity, Immediate | 3 | 2004 | 62 | 0.420 |
Why?
|
Cell Line, Tumor | 14 | 2019 | 2421 | 0.420 |
Why?
|
Amantadine | 6 | 2007 | 18 | 0.420 |
Why?
|
Music | 2 | 2023 | 34 | 0.410 |
Why?
|
History, 21st Century | 3 | 2018 | 175 | 0.410 |
Why?
|
Chromosomes, Human, Pair 6 | 8 | 2013 | 125 | 0.410 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 22 | 0.400 |
Why?
|
Cell Membrane | 2 | 2014 | 664 | 0.400 |
Why?
|
Research Design | 10 | 2021 | 594 | 0.390 |
Why?
|
Body Mass Index | 10 | 2014 | 770 | 0.390 |
Why?
|
Tinnitus | 2 | 2022 | 21 | 0.380 |
Why?
|
Metabolic Syndrome | 5 | 2020 | 141 | 0.370 |
Why?
|
Bipolar Disorder | 8 | 2014 | 377 | 0.370 |
Why?
|
Liver | 9 | 2016 | 1229 | 0.370 |
Why?
|
Risk Assessment | 6 | 2020 | 2253 | 0.370 |
Why?
|
China | 7 | 2019 | 228 | 0.370 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2020 | 236 | 0.360 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 247 | 0.360 |
Why?
|
Insulin Resistance | 6 | 2017 | 377 | 0.360 |
Why?
|
Health Literacy | 1 | 2010 | 70 | 0.350 |
Why?
|
Young Adult | 22 | 2019 | 5961 | 0.350 |
Why?
|
Sepsis | 2 | 2023 | 304 | 0.350 |
Why?
|
Virulence | 12 | 2014 | 270 | 0.350 |
Why?
|
Models, Statistical | 5 | 2012 | 574 | 0.350 |
Why?
|
Respiratory Mucosa | 4 | 2014 | 86 | 0.350 |
Why?
|
Carboplatin | 6 | 2011 | 286 | 0.350 |
Why?
|
Mendelian Randomization Analysis | 4 | 2023 | 43 | 0.350 |
Why?
|
Cognitive Reserve | 2 | 2020 | 5 | 0.350 |
Why?
|
Environmental Exposure | 2 | 2011 | 296 | 0.350 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2022 | 183 | 0.340 |
Why?
|
DNA-Binding Proteins | 8 | 2023 | 1208 | 0.340 |
Why?
|
DNA | 13 | 2019 | 1293 | 0.340 |
Why?
|
Aged, 80 and over | 24 | 2021 | 6481 | 0.340 |
Why?
|
Mice, Inbred BALB C | 17 | 2014 | 1047 | 0.340 |
Why?
|
Receptors, Virus | 5 | 2011 | 74 | 0.330 |
Why?
|
Hypertension | 4 | 2023 | 1139 | 0.330 |
Why?
|
Patient Education as Topic | 2 | 2010 | 351 | 0.330 |
Why?
|
Neurotoxicity Syndromes | 2 | 2022 | 28 | 0.330 |
Why?
|
Pharmaceutical Preparations | 3 | 2022 | 92 | 0.330 |
Why?
|
Sample Size | 4 | 2018 | 130 | 0.330 |
Why?
|
Cluster Analysis | 7 | 2023 | 369 | 0.330 |
Why?
|
Chromosomes, Human, Pair 11 | 7 | 2006 | 106 | 0.320 |
Why?
|
Family | 7 | 2005 | 311 | 0.320 |
Why?
|
Aging | 5 | 2020 | 689 | 0.320 |
Why?
|
Protein Isoforms | 1 | 2008 | 269 | 0.310 |
Why?
|
Chromosomes, Human | 4 | 2008 | 66 | 0.310 |
Why?
|
Mice | 31 | 2021 | 11313 | 0.310 |
Why?
|
Genes | 4 | 2014 | 305 | 0.310 |
Why?
|
Hemagglutination Inhibition Tests | 14 | 2009 | 37 | 0.310 |
Why?
|
Swine | 10 | 2013 | 554 | 0.300 |
Why?
|
Chickens | 9 | 2015 | 212 | 0.300 |
Why?
|
Texas | 8 | 2016 | 101 | 0.300 |
Why?
|
Likelihood Functions | 8 | 2006 | 251 | 0.300 |
Why?
|
Guidelines as Topic | 2 | 2021 | 162 | 0.300 |
Why?
|
Biopsy | 3 | 2021 | 1160 | 0.290 |
Why?
|
Rare Diseases | 3 | 2021 | 59 | 0.290 |
Why?
|
Receptor, Insulin | 5 | 2002 | 54 | 0.290 |
Why?
|
Vaccines, Inactivated | 10 | 2011 | 29 | 0.290 |
Why?
|
Mutation, Missense | 10 | 2023 | 276 | 0.290 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2018 | 302 | 0.290 |
Why?
|
Mexico | 7 | 2016 | 67 | 0.280 |
Why?
|
Rimantadine | 5 | 2007 | 9 | 0.280 |
Why?
|
Aorta | 2 | 2018 | 280 | 0.280 |
Why?
|
Signal Transduction | 9 | 2021 | 3233 | 0.280 |
Why?
|
Linear Models | 7 | 2017 | 419 | 0.270 |
Why?
|
Hemagglutinins | 3 | 2015 | 19 | 0.270 |
Why?
|
American Heart Association | 2 | 2023 | 92 | 0.270 |
Why?
|
Diabetes Mellitus | 4 | 2007 | 801 | 0.270 |
Why?
|
Age Factors | 15 | 2020 | 1842 | 0.270 |
Why?
|
Oligonucleotides | 4 | 1989 | 92 | 0.260 |
Why?
|
Host-Pathogen Interactions | 5 | 2020 | 230 | 0.260 |
Why?
|
Amino Acid Substitution | 11 | 2016 | 339 | 0.260 |
Why?
|
Viral Core Proteins | 4 | 2014 | 27 | 0.260 |
Why?
|
Arthritis, Rheumatoid | 3 | 2020 | 163 | 0.260 |
Why?
|
Endocytosis | 2 | 2021 | 177 | 0.260 |
Why?
|
Adipose Tissue | 4 | 2016 | 240 | 0.250 |
Why?
|
Germ-Line Mutation | 6 | 2020 | 329 | 0.250 |
Why?
|
Disease Models, Animal | 15 | 2020 | 2227 | 0.250 |
Why?
|
Viral Matrix Proteins | 4 | 2011 | 14 | 0.250 |
Why?
|
Knowledge Bases | 2 | 2021 | 14 | 0.250 |
Why?
|
Hyperlipidemias | 2 | 2022 | 95 | 0.250 |
Why?
|
DNA, Neoplasm | 3 | 2014 | 265 | 0.250 |
Why?
|
Temperature | 6 | 2014 | 395 | 0.250 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 476 | 0.240 |
Why?
|
Glaucoma, Open-Angle | 1 | 2024 | 17 | 0.240 |
Why?
|
Day Care, Medical | 4 | 1999 | 11 | 0.240 |
Why?
|
HSP40 Heat-Shock Proteins | 2 | 2016 | 18 | 0.240 |
Why?
|
Cell Proliferation | 5 | 2024 | 1571 | 0.240 |
Why?
|
Neoplasm Proteins | 4 | 2017 | 532 | 0.240 |
Why?
|
Intellectual Disability | 3 | 2021 | 185 | 0.240 |
Why?
|
Inflammation | 3 | 2021 | 913 | 0.240 |
Why?
|
Hidradenitis Suppurativa | 1 | 2023 | 11 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.230 |
Why?
|
Mosaicism | 1 | 2023 | 67 | 0.230 |
Why?
|
Acne Vulgaris | 1 | 2023 | 32 | 0.230 |
Why?
|
Disease Transmission, Infectious | 2 | 2002 | 57 | 0.230 |
Why?
|
Sex Characteristics | 4 | 2022 | 319 | 0.230 |
Why?
|
HLA Antigens | 6 | 2004 | 232 | 0.230 |
Why?
|
Actinobacteria | 1 | 2023 | 11 | 0.230 |
Why?
|
Exfoliation Syndrome | 1 | 2023 | 1 | 0.230 |
Why?
|
Influenza A Virus, H7N3 Subtype | 2 | 2013 | 3 | 0.230 |
Why?
|
Cholesterol, LDL | 3 | 2023 | 222 | 0.230 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2020 | 57 | 0.230 |
Why?
|
Membrane Transport Proteins | 5 | 2017 | 166 | 0.230 |
Why?
|
Multimorbidity | 1 | 2023 | 5 | 0.230 |
Why?
|
Carrier Proteins | 5 | 2017 | 672 | 0.230 |
Why?
|
Hong Kong | 15 | 2007 | 45 | 0.230 |
Why?
|
Promoter Regions, Genetic | 5 | 2020 | 937 | 0.230 |
Why?
|
Computer Simulation | 12 | 2024 | 1077 | 0.220 |
Why?
|
Multiple Sclerosis | 2 | 2022 | 261 | 0.220 |
Why?
|
Virus Attachment | 2 | 2014 | 6 | 0.220 |
Why?
|
Biological Evolution | 7 | 2019 | 917 | 0.220 |
Why?
|
HLA-DR Antigens | 5 | 1991 | 61 | 0.220 |
Why?
|
Otitis Media | 1 | 2022 | 18 | 0.220 |
Why?
|
Islets of Langerhans | 8 | 2006 | 544 | 0.220 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2014 | 150 | 0.220 |
Why?
|
Adamantane | 3 | 2008 | 8 | 0.220 |
Why?
|
Language Development Disorders | 2 | 2020 | 24 | 0.220 |
Why?
|
Platinum | 2 | 2014 | 63 | 0.220 |
Why?
|
Principal Component Analysis | 4 | 2020 | 155 | 0.220 |
Why?
|
Candidiasis | 1 | 2022 | 36 | 0.220 |
Why?
|
Chromosomes, Human, Pair 1 | 4 | 2007 | 100 | 0.220 |
Why?
|
Telomere | 1 | 2023 | 107 | 0.220 |
Why?
|
Leadership | 1 | 2024 | 134 | 0.220 |
Why?
|
Mercaptopurine | 1 | 2022 | 53 | 0.210 |
Why?
|
Viral Nonstructural Proteins | 3 | 2020 | 37 | 0.210 |
Why?
|
Hepatitis B | 1 | 2022 | 72 | 0.210 |
Why?
|
Receptors, Cell Surface | 3 | 2021 | 286 | 0.210 |
Why?
|
Herpes Zoster | 1 | 2022 | 78 | 0.210 |
Why?
|
Risk | 10 | 2019 | 673 | 0.210 |
Why?
|
Chromosomes, Human, Pair 12 | 3 | 2005 | 65 | 0.210 |
Why?
|
Speech Perception | 1 | 2022 | 71 | 0.210 |
Why?
|
Fasting | 4 | 2017 | 161 | 0.210 |
Why?
|
Odds Ratio | 7 | 2021 | 677 | 0.210 |
Why?
|
Genome | 3 | 2021 | 371 | 0.210 |
Why?
|
Drug Repositioning | 1 | 2022 | 22 | 0.210 |
Why?
|
Overweight | 1 | 2023 | 118 | 0.210 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2021 | 21 | 0.210 |
Why?
|
Shock, Septic | 1 | 2023 | 102 | 0.210 |
Why?
|
DiGeorge Syndrome | 1 | 2021 | 14 | 0.210 |
Why?
|
Poultry | 7 | 2013 | 22 | 0.210 |
Why?
|
Homeodomain Proteins | 4 | 2018 | 535 | 0.210 |
Why?
|
Capecitabine | 2 | 2020 | 95 | 0.210 |
Why?
|
Phosphoproteins | 4 | 2009 | 253 | 0.210 |
Why?
|
Duffy Blood-Group System | 1 | 2021 | 7 | 0.210 |
Why?
|
Communicable Diseases | 1 | 2022 | 63 | 0.210 |
Why?
|
Physicians | 2 | 2013 | 672 | 0.210 |
Why?
|
Nuclear Proteins | 5 | 2017 | 694 | 0.210 |
Why?
|
Viral Structural Proteins | 2 | 2007 | 19 | 0.210 |
Why?
|
Bone Marrow Diseases | 1 | 2021 | 40 | 0.210 |
Why?
|
Time Factors | 13 | 2018 | 5198 | 0.210 |
Why?
|
Anemia | 1 | 2022 | 128 | 0.210 |
Why?
|
Ducks | 3 | 2009 | 8 | 0.210 |
Why?
|
Shear Strength | 1 | 2021 | 19 | 0.200 |
Why?
|
Zebrafish | 3 | 2020 | 307 | 0.200 |
Why?
|
Membrane Proteins | 4 | 2023 | 1194 | 0.200 |
Why?
|
Russia | 4 | 2013 | 25 | 0.200 |
Why?
|
Environment | 5 | 2017 | 219 | 0.200 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2023 | 407 | 0.200 |
Why?
|
Bone Marrow Examination | 1 | 2021 | 48 | 0.200 |
Why?
|
Chromosome Disorders | 1 | 2021 | 114 | 0.200 |
Why?
|
Hyperglycemia | 3 | 2012 | 176 | 0.200 |
Why?
|
Introns | 5 | 2017 | 289 | 0.200 |
Why?
|
Thrombocytopenia | 1 | 2022 | 183 | 0.200 |
Why?
|
Lymphocytes | 2 | 2018 | 461 | 0.200 |
Why?
|
Kidney Diseases | 2 | 2023 | 418 | 0.200 |
Why?
|
Virus Shedding | 4 | 2011 | 26 | 0.200 |
Why?
|
Triglycerides | 2 | 2017 | 232 | 0.200 |
Why?
|
Dermatitis, Atopic | 1 | 2021 | 51 | 0.200 |
Why?
|
Kidney Tubules, Proximal | 1 | 2021 | 61 | 0.200 |
Why?
|
Biomedical Research | 2 | 2017 | 375 | 0.200 |
Why?
|
Child Day Care Centers | 1 | 2000 | 6 | 0.200 |
Why?
|
Japan | 11 | 2022 | 307 | 0.200 |
Why?
|
Chromosome Deletion | 1 | 2021 | 228 | 0.190 |
Why?
|
International Cooperation | 2 | 2019 | 126 | 0.190 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 7 | 1991 | 30 | 0.190 |
Why?
|
Virulence Factors | 2 | 2014 | 108 | 0.190 |
Why?
|
Periodicity | 1 | 2021 | 119 | 0.190 |
Why?
|
Birds | 6 | 2014 | 157 | 0.190 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 1610 | 0.190 |
Why?
|
Metabolic Diseases | 1 | 2021 | 48 | 0.190 |
Why?
|
Neutropenia | 1 | 2021 | 215 | 0.190 |
Why?
|
Protein Transport | 5 | 2020 | 410 | 0.190 |
Why?
|
Cigarette Smoking | 1 | 2021 | 27 | 0.190 |
Why?
|
Haploinsufficiency | 1 | 2021 | 62 | 0.190 |
Why?
|
Dementia | 4 | 2020 | 187 | 0.190 |
Why?
|
Diabetic Retinopathy | 2 | 2012 | 84 | 0.190 |
Why?
|
Europe | 9 | 2016 | 308 | 0.190 |
Why?
|
Recombination, Genetic | 10 | 2005 | 439 | 0.190 |
Why?
|
Genetic Pleiotropy | 1 | 2020 | 24 | 0.190 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2020 | 20 | 0.190 |
Why?
|
Biological Transport | 1 | 2021 | 396 | 0.190 |
Why?
|
Prognosis | 8 | 2021 | 3669 | 0.190 |
Why?
|
Alcoholism | 2 | 2021 | 170 | 0.190 |
Why?
|
Genes, Regulator | 3 | 1989 | 65 | 0.190 |
Why?
|
Chronic Pain | 1 | 2023 | 145 | 0.190 |
Why?
|
Songbirds | 1 | 2021 | 83 | 0.190 |
Why?
|
Language Development | 2 | 2015 | 23 | 0.190 |
Why?
|
DEAD Box Protein 58 | 1 | 2020 | 11 | 0.190 |
Why?
|
Receptors, Interleukin-4 | 1 | 2000 | 9 | 0.190 |
Why?
|
Retrospective Studies | 13 | 2023 | 8431 | 0.190 |
Why?
|
Genotyping Techniques | 3 | 2016 | 68 | 0.190 |
Why?
|
Prevalence | 6 | 2019 | 1239 | 0.190 |
Why?
|
Autism Spectrum Disorder | 2 | 2021 | 76 | 0.190 |
Why?
|
Vocalization, Animal | 1 | 2021 | 100 | 0.190 |
Why?
|
Hospitalization | 7 | 2014 | 844 | 0.190 |
Why?
|
Information Storage and Retrieval | 1 | 2020 | 120 | 0.180 |
Why?
|
Societies, Medical | 1 | 2024 | 572 | 0.180 |
Why?
|
Nuclear Family | 8 | 2002 | 92 | 0.180 |
Why?
|
Leukopenia | 1 | 2020 | 65 | 0.180 |
Why?
|
Cognitive Aging | 1 | 2019 | 8 | 0.180 |
Why?
|
Selection, Genetic | 5 | 2021 | 502 | 0.180 |
Why?
|
Tobacco Use Disorder | 1 | 2021 | 108 | 0.180 |
Why?
|
Apolipoprotein E4 | 1 | 2019 | 27 | 0.180 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2015 | 755 | 0.180 |
Why?
|
Cardiology | 1 | 2021 | 123 | 0.180 |
Why?
|
Neanderthals | 1 | 2019 | 15 | 0.180 |
Why?
|
Membrane Glycoproteins | 4 | 2009 | 428 | 0.180 |
Why?
|
Chromosomes, Human, Pair 20 | 4 | 2004 | 32 | 0.180 |
Why?
|
Time-to-Treatment | 1 | 2020 | 97 | 0.180 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2020 | 73 | 0.180 |
Why?
|
Neuroblastoma | 2 | 2014 | 374 | 0.180 |
Why?
|
DNA Probes | 3 | 1990 | 77 | 0.180 |
Why?
|
Proteomics | 3 | 2023 | 211 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2017 | 321 | 0.180 |
Why?
|
Tic Disorders | 1 | 2019 | 8 | 0.180 |
Why?
|
Post-Concussion Syndrome | 1 | 2019 | 7 | 0.180 |
Why?
|
HEK293 Cells | 4 | 2014 | 615 | 0.170 |
Why?
|
Bayes Theorem | 6 | 2021 | 360 | 0.170 |
Why?
|
Tandem Mass Spectrometry | 2 | 2011 | 103 | 0.170 |
Why?
|
Pregnancy Complications | 3 | 2012 | 336 | 0.170 |
Why?
|
Endophenotypes | 2 | 2017 | 17 | 0.170 |
Why?
|
Infant, Newborn | 12 | 2019 | 2369 | 0.170 |
Why?
|
Pregnancy | 13 | 2014 | 2885 | 0.170 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 347 | 0.170 |
Why?
|
Coronary Disease | 2 | 2018 | 261 | 0.170 |
Why?
|
Etoposide | 2 | 2011 | 196 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 339 | 0.170 |
Why?
|
Lipoprotein(a) | 1 | 2018 | 28 | 0.170 |
Why?
|
Prefrontal Cortex | 1 | 2020 | 129 | 0.170 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2020 | 96 | 0.170 |
Why?
|
Eggs | 2 | 2015 | 12 | 0.170 |
Why?
|
ATP-Binding Cassette Transporters | 6 | 2014 | 141 | 0.170 |
Why?
|
Dogs | 9 | 2011 | 684 | 0.170 |
Why?
|
Precision Medicine | 3 | 2023 | 394 | 0.170 |
Why?
|
Meta-Analysis as Topic | 5 | 2021 | 87 | 0.170 |
Why?
|
Muscle Proteins | 2 | 2018 | 132 | 0.170 |
Why?
|
Serpins | 1 | 2018 | 29 | 0.170 |
Why?
|
tau Proteins | 3 | 2019 | 62 | 0.170 |
Why?
|
DNA Primers | 11 | 2002 | 542 | 0.170 |
Why?
|
Immunization | 2 | 2006 | 158 | 0.170 |
Why?
|
Statistical Distributions | 1 | 2018 | 9 | 0.160 |
Why?
|
Zebrafish Proteins | 1 | 2020 | 144 | 0.160 |
Why?
|
Hominidae | 1 | 2019 | 95 | 0.160 |
Why?
|
Glucose | 5 | 2012 | 637 | 0.160 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2012 | 276 | 0.160 |
Why?
|
Aortic Rupture | 1 | 2018 | 55 | 0.160 |
Why?
|
Abnormalities, Multiple | 1 | 2020 | 232 | 0.160 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2010 | 108 | 0.160 |
Why?
|
Epidemics | 1 | 2018 | 33 | 0.160 |
Why?
|
Claudins | 1 | 2018 | 31 | 0.160 |
Why?
|
Learning | 1 | 2021 | 279 | 0.160 |
Why?
|
Rectum | 1 | 2019 | 146 | 0.160 |
Why?
|
Sequence Analysis, RNA | 3 | 2016 | 217 | 0.160 |
Why?
|
Cognition Disorders | 2 | 2010 | 236 | 0.160 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 241 | 0.160 |
Why?
|
DNA Mutational Analysis | 5 | 2018 | 526 | 0.160 |
Why?
|
Alcohol Drinking | 1 | 2021 | 264 | 0.160 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 345 | 0.160 |
Why?
|
Proteins | 4 | 2014 | 777 | 0.160 |
Why?
|
Influenza A Virus, H9N2 Subtype | 3 | 2003 | 8 | 0.160 |
Why?
|
Chick Embryo | 8 | 2015 | 229 | 0.160 |
Why?
|
Kidney Failure, Chronic | 1 | 2023 | 509 | 0.160 |
Why?
|
Glucose Tolerance Test | 8 | 2017 | 228 | 0.160 |
Why?
|
Health Resources | 1 | 2018 | 76 | 0.160 |
Why?
|
Pemetrexed | 1 | 2018 | 76 | 0.160 |
Why?
|
Inheritance Patterns | 5 | 2019 | 48 | 0.160 |
Why?
|
Oseltamivir | 3 | 2014 | 20 | 0.160 |
Why?
|
Insurance Claim Reporting | 1 | 2017 | 3 | 0.160 |
Why?
|
Repressor Proteins | 2 | 2020 | 403 | 0.160 |
Why?
|
Models, Cardiovascular | 1 | 2018 | 98 | 0.160 |
Why?
|
Contactins | 1 | 2017 | 2 | 0.160 |
Why?
|
Adaptation, Psychological | 2 | 2017 | 157 | 0.160 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2017 | 29 | 0.150 |
Why?
|
Ubiquitin-Specific Proteases | 1 | 2017 | 1 | 0.150 |
Why?
|
Apolipoprotein A-V | 1 | 2017 | 1 | 0.150 |
Why?
|
Amyloidogenic Proteins | 1 | 2017 | 13 | 0.150 |
Why?
|
Skin Pigmentation | 1 | 2017 | 40 | 0.150 |
Why?
|
Dyslipidemias | 1 | 2018 | 109 | 0.150 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2017 | 13 | 0.150 |
Why?
|
Adiposity | 2 | 2017 | 70 | 0.150 |
Why?
|
Potassium Channels | 6 | 2007 | 340 | 0.150 |
Why?
|
Apolipoproteins C | 1 | 1996 | 5 | 0.150 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 62 | 0.150 |
Why?
|
Heat-Shock Proteins | 2 | 2008 | 178 | 0.150 |
Why?
|
RNA, Messenger | 7 | 2023 | 1975 | 0.150 |
Why?
|
Databases, Nucleic Acid | 2 | 2015 | 41 | 0.150 |
Why?
|
Polysaccharides | 3 | 2012 | 89 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2007 | 69 | 0.150 |
Why?
|
Gastrointestinal Microbiome | 1 | 2023 | 451 | 0.150 |
Why?
|
Myocardium | 2 | 2016 | 528 | 0.150 |
Why?
|
Nucleoproteins | 4 | 2011 | 21 | 0.150 |
Why?
|
Cognition | 3 | 2023 | 570 | 0.150 |
Why?
|
Age of Onset | 6 | 2017 | 306 | 0.150 |
Why?
|
Lipid Metabolism | 2 | 2016 | 196 | 0.150 |
Why?
|
Receptors, Drug | 5 | 2007 | 54 | 0.150 |
Why?
|
Comorbidity | 4 | 2022 | 943 | 0.140 |
Why?
|
Bronchi | 4 | 2012 | 229 | 0.140 |
Why?
|
RNA, Small Interfering | 5 | 2020 | 547 | 0.140 |
Why?
|
Inhibitory Concentration 50 | 3 | 2011 | 64 | 0.140 |
Why?
|
Immunity, Innate | 1 | 2020 | 405 | 0.140 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 2 | 2014 | 8 | 0.140 |
Why?
|
Cross Protection | 2 | 2017 | 8 | 0.140 |
Why?
|
Christianity | 3 | 2001 | 36 | 0.140 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2016 | 24 | 0.140 |
Why?
|
Serotonin | 2 | 2017 | 218 | 0.140 |
Why?
|
Cross Reactions | 6 | 2012 | 106 | 0.140 |
Why?
|
Follow-Up Studies | 9 | 2021 | 3616 | 0.140 |
Why?
|
Virus Cultivation | 5 | 2015 | 20 | 0.140 |
Why?
|
Hypertriglyceridemia | 1 | 1996 | 67 | 0.140 |
Why?
|
Heart Conduction System | 1 | 2016 | 108 | 0.140 |
Why?
|
Transcription, Genetic | 3 | 2020 | 1135 | 0.140 |
Why?
|
RNA Splicing | 1 | 2017 | 142 | 0.140 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 4 | 2010 | 45 | 0.140 |
Why?
|
Muscle, Skeletal | 3 | 2014 | 448 | 0.140 |
Why?
|
Forkhead Transcription Factors | 1 | 2017 | 166 | 0.140 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 316 | 0.140 |
Why?
|
Ribonucleoproteins | 1 | 2016 | 38 | 0.140 |
Why?
|
Whole Genome Sequencing | 3 | 2021 | 76 | 0.140 |
Why?
|
Severe Combined Immunodeficiency | 1 | 1995 | 17 | 0.140 |
Why?
|
Fibroblasts | 2 | 2020 | 729 | 0.140 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 73 | 0.140 |
Why?
|
Bone Marrow Transplantation | 2 | 1998 | 285 | 0.140 |
Why?
|
DNA, Viral | 7 | 2002 | 265 | 0.140 |
Why?
|
Neurons | 3 | 2021 | 1545 | 0.140 |
Why?
|
Potassium Channels, Inwardly Rectifying | 5 | 2007 | 118 | 0.140 |
Why?
|
Geese | 2 | 2009 | 7 | 0.140 |
Why?
|
Heredity | 1 | 2015 | 19 | 0.130 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 43 | 0.130 |
Why?
|
Birth Weight | 2 | 2013 | 144 | 0.130 |
Why?
|
Severity of Illness Index | 3 | 2019 | 1796 | 0.130 |
Why?
|
Melanoma | 2 | 2017 | 454 | 0.130 |
Why?
|
Neutralization Tests | 8 | 2009 | 77 | 0.130 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 279 | 0.130 |
Why?
|
Mothers | 2 | 2010 | 140 | 0.130 |
Why?
|
Homeostasis | 3 | 2014 | 408 | 0.130 |
Why?
|
Virion | 2 | 1995 | 59 | 0.130 |
Why?
|
Glucose-6-Phosphatase | 1 | 2015 | 8 | 0.130 |
Why?
|
Rural Population | 2 | 2011 | 136 | 0.130 |
Why?
|
Respite Care | 2 | 1997 | 9 | 0.130 |
Why?
|
Sleep Apnea Syndromes | 1 | 2016 | 102 | 0.130 |
Why?
|
In Vitro Techniques | 3 | 2014 | 987 | 0.130 |
Why?
|
Vaccines, Synthetic | 5 | 2014 | 55 | 0.130 |
Why?
|
Germany | 5 | 2007 | 72 | 0.130 |
Why?
|
Vitamin K Epoxide Reductases | 2 | 2013 | 16 | 0.130 |
Why?
|
Civil Defense | 1 | 2014 | 11 | 0.130 |
Why?
|
Baculoviridae | 1 | 1995 | 34 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2017 | 541 | 0.130 |
Why?
|
Nedocromil | 1 | 2014 | 6 | 0.130 |
Why?
|
Cytochrome P-450 CYP2C9 | 2 | 2013 | 21 | 0.130 |
Why?
|
Sampling Studies | 4 | 2008 | 70 | 0.130 |
Why?
|
DNA Restriction Enzymes | 7 | 1991 | 98 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 645 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 85 | 0.130 |
Why?
|
Smoking | 3 | 2023 | 605 | 0.130 |
Why?
|
Monosaccharide Transport Proteins | 3 | 1990 | 73 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 81 | 0.130 |
Why?
|
Regression Analysis | 3 | 2011 | 595 | 0.130 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2006 | 85 | 0.130 |
Why?
|
Poultry Diseases | 3 | 2009 | 13 | 0.130 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 977 | 0.130 |
Why?
|
Hyperinsulinism | 2 | 2010 | 51 | 0.130 |
Why?
|
Cell Cycle Proteins | 1 | 2017 | 388 | 0.130 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 378 | 0.120 |
Why?
|
Nerve Growth Factors | 1 | 2014 | 63 | 0.120 |
Why?
|
Actinin | 1 | 2014 | 19 | 0.120 |
Why?
|
Oxo-Acid-Lyases | 1 | 2014 | 7 | 0.120 |
Why?
|
Forced Expiratory Volume | 1 | 2014 | 121 | 0.120 |
Why?
|
Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.120 |
Why?
|
Bias | 2 | 2005 | 127 | 0.120 |
Why?
|
Quality Control | 2 | 2014 | 117 | 0.120 |
Why?
|
Cytosine | 1 | 2015 | 127 | 0.120 |
Why?
|
Euphoria | 1 | 2014 | 43 | 0.120 |
Why?
|
Consanguinity | 4 | 2005 | 73 | 0.120 |
Why?
|
Genetics, Behavioral | 1 | 1993 | 22 | 0.120 |
Why?
|
Age Distribution | 6 | 2014 | 204 | 0.120 |
Why?
|
Family Health | 5 | 2017 | 162 | 0.120 |
Why?
|
Myocytes, Cardiac | 1 | 2016 | 275 | 0.120 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2013 | 27 | 0.120 |
Why?
|
Antarctic Regions | 1 | 2013 | 5 | 0.120 |
Why?
|
Pacific Ocean | 1 | 2013 | 16 | 0.120 |
Why?
|
Survival Analysis | 5 | 2021 | 1536 | 0.120 |
Why?
|
Genomic Imprinting | 2 | 2010 | 33 | 0.120 |
Why?
|
Anti-Asthmatic Agents | 1 | 2014 | 76 | 0.120 |
Why?
|
Therapeutics | 1 | 2013 | 12 | 0.120 |
Why?
|
Cholesterol | 3 | 2023 | 356 | 0.120 |
Why?
|
Muscles | 2 | 2012 | 192 | 0.120 |
Why?
|
Oligoribonucleotides | 2 | 1984 | 28 | 0.120 |
Why?
|
Air | 1 | 2013 | 62 | 0.120 |
Why?
|
Risk Reduction Behavior | 2 | 2011 | 98 | 0.120 |
Why?
|
Femoral Neck Fractures | 1 | 2013 | 11 | 0.120 |
Why?
|
Proteinase Inhibitory Proteins, Secretory | 1 | 2013 | 2 | 0.120 |
Why?
|
Vitamin K | 1 | 2013 | 25 | 0.120 |
Why?
|
Sleep | 1 | 2017 | 440 | 0.120 |
Why?
|
Clusterin | 1 | 2013 | 13 | 0.120 |
Why?
|
Viral Tropism | 1 | 2013 | 4 | 0.120 |
Why?
|
Conjunctivitis | 1 | 2013 | 6 | 0.120 |
Why?
|
Seawater | 1 | 2013 | 42 | 0.120 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2013 | 66 | 0.120 |
Why?
|
Catechol O-Methyltransferase | 1 | 2013 | 65 | 0.110 |
Why?
|
Antifibrinolytic Agents | 1 | 2013 | 30 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 2434 | 0.110 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2016 | 217 | 0.110 |
Why?
|
Cyclins | 1 | 2013 | 82 | 0.110 |
Why?
|
Lung Diseases, Obstructive | 1 | 1993 | 19 | 0.110 |
Why?
|
Analysis of Variance | 2 | 2014 | 912 | 0.110 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2013 | 93 | 0.110 |
Why?
|
DNA Methylation | 2 | 2021 | 622 | 0.110 |
Why?
|
Receptors, GABA-A | 2 | 2009 | 32 | 0.110 |
Why?
|
Dextroamphetamine | 1 | 2014 | 107 | 0.110 |
Why?
|
Protein Interaction Maps | 1 | 2013 | 48 | 0.110 |
Why?
|
Treatment Failure | 3 | 2014 | 284 | 0.110 |
Why?
|
Conserved Sequence | 3 | 2006 | 210 | 0.110 |
Why?
|
Fibrillar Collagens | 1 | 2012 | 10 | 0.110 |
Why?
|
Lipids | 2 | 2016 | 269 | 0.110 |
Why?
|
Heart Failure | 1 | 2022 | 1196 | 0.110 |
Why?
|
Leukemia, Myeloid | 2 | 2009 | 249 | 0.110 |
Why?
|
Statistics as Topic | 3 | 2020 | 237 | 0.110 |
Why?
|
Universities | 1 | 2013 | 135 | 0.110 |
Why?
|
HLA-DQ Antigens | 2 | 1991 | 52 | 0.110 |
Why?
|
Leucine | 2 | 2003 | 67 | 0.110 |
Why?
|
Sulfonamides | 1 | 2014 | 299 | 0.110 |
Why?
|
Cytarabine | 1 | 2013 | 218 | 0.110 |
Why?
|
Membrane Potentials | 1 | 2014 | 435 | 0.110 |
Why?
|
Surveys and Questionnaires | 2 | 2012 | 2495 | 0.110 |
Why?
|
Cholesterol, HDL | 2 | 2023 | 165 | 0.110 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2013 | 90 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2018 | 7949 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 309 | 0.110 |
Why?
|
Cold Temperature | 6 | 2003 | 157 | 0.110 |
Why?
|
Outpatients | 3 | 2020 | 94 | 0.110 |
Why?
|
Nitriles | 1 | 2012 | 145 | 0.110 |
Why?
|
Logistic Models | 4 | 2018 | 1184 | 0.110 |
Why?
|
Apoptosis | 3 | 2013 | 1678 | 0.110 |
Why?
|
Somatomedins | 2 | 1988 | 28 | 0.100 |
Why?
|
Insulin-Like Growth Factor II | 2 | 1988 | 33 | 0.100 |
Why?
|
Postmenopause | 1 | 2012 | 98 | 0.100 |
Why?
|
Triazoles | 1 | 2012 | 96 | 0.100 |
Why?
|
Public Health | 1 | 2013 | 129 | 0.100 |
Why?
|
Pyrimidines | 1 | 2014 | 370 | 0.100 |
Why?
|
ErbB Receptors | 2 | 2021 | 485 | 0.100 |
Why?
|
Metabolomics | 1 | 2012 | 67 | 0.100 |
Why?
|
Macular Edema | 1 | 2012 | 48 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 1 | 2012 | 176 | 0.100 |
Why?
|
Evolution, Molecular | 6 | 2016 | 813 | 0.100 |
Why?
|
Glutathione Transferase | 2 | 2008 | 111 | 0.100 |
Why?
|
Genealogy and Heraldry | 1 | 2011 | 13 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 645 | 0.100 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2011 | 26 | 0.100 |
Why?
|
Telomerase | 1 | 2011 | 55 | 0.100 |
Why?
|
Hemorrhage | 1 | 2013 | 265 | 0.100 |
Why?
|
Rural Health Services | 1 | 2011 | 13 | 0.100 |
Why?
|
Mesothelioma | 2 | 2011 | 309 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 2012 | 163 | 0.100 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 94 | 0.100 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2011 | 63 | 0.100 |
Why?
|
eIF-2 Kinase | 1 | 2011 | 46 | 0.100 |
Why?
|
Mineral Fibers | 1 | 2011 | 2 | 0.100 |
Why?
|
Daunorubicin | 1 | 2011 | 78 | 0.100 |
Why?
|
Protein Binding | 5 | 2016 | 1454 | 0.100 |
Why?
|
Cost of Illness | 6 | 2010 | 150 | 0.100 |
Why?
|
Virology | 1 | 2011 | 9 | 0.100 |
Why?
|
Cloning, Molecular | 5 | 2011 | 646 | 0.100 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2008 | 43 | 0.100 |
Why?
|
Chiroptera | 1 | 2012 | 51 | 0.100 |
Why?
|
Adenosine Deaminase | 1 | 1991 | 20 | 0.100 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2002 | 30 | 0.100 |
Why?
|
Rats, Sprague-Dawley | 1 | 2014 | 1214 | 0.100 |
Why?
|
Community Networks | 1 | 2011 | 29 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2014 | 427 | 0.100 |
Why?
|
Consumer Health Information | 1 | 2010 | 13 | 0.100 |
Why?
|
Phosphorylation | 4 | 2020 | 1101 | 0.100 |
Why?
|
Paclitaxel | 1 | 2012 | 460 | 0.100 |
Why?
|
Rats | 4 | 2014 | 3984 | 0.100 |
Why?
|
Lung | 6 | 2014 | 1167 | 0.100 |
Why?
|
Population Groups | 1 | 2010 | 41 | 0.100 |
Why?
|
Cells, Cultured | 2 | 2014 | 2810 | 0.100 |
Why?
|
Gene-Environment Interaction | 1 | 2011 | 103 | 0.100 |
Why?
|
Immunization Schedule | 2 | 2009 | 21 | 0.100 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.100 |
Why?
|
TCF Transcription Factors | 1 | 2010 | 23 | 0.100 |
Why?
|
Quality of Life | 4 | 2021 | 1575 | 0.100 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 55 | 0.100 |
Why?
|
Influenza A Virus, H5N2 Subtype | 2 | 2009 | 3 | 0.100 |
Why?
|
Virus Diseases | 1 | 2011 | 96 | 0.100 |
Why?
|
Deoxycytidine | 1 | 2012 | 237 | 0.100 |
Why?
|
Adenocarcinoma | 1 | 2018 | 1160 | 0.090 |
Why?
|
Molecular Sequence Annotation | 2 | 2023 | 67 | 0.090 |
Why?
|
GTP-Binding Proteins | 1 | 1991 | 146 | 0.090 |
Why?
|
Asparaginase | 1 | 2010 | 34 | 0.090 |
Why?
|
Pregnancy in Diabetics | 1 | 2010 | 37 | 0.090 |
Why?
|
Internet | 1 | 2013 | 309 | 0.090 |
Why?
|
Respiratory Tract Infections | 1 | 2011 | 104 | 0.090 |
Why?
|
Environmental Pollutants | 1 | 2011 | 50 | 0.090 |
Why?
|
Drug Hypersensitivity | 1 | 2010 | 37 | 0.090 |
Why?
|
Models, Molecular | 6 | 2014 | 1284 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
Genetic Techniques | 2 | 2005 | 72 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2010 | 131 | 0.090 |
Why?
|
Hippocampus | 1 | 2014 | 442 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2011 | 315 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 1958 | 0.090 |
Why?
|
Receptors, AMPA | 1 | 2010 | 66 | 0.090 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 1708 | 0.090 |
Why?
|
Antigens, CD | 1 | 2012 | 457 | 0.090 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 1671 | 0.090 |
Why?
|
Calcium-Binding Proteins | 2 | 2023 | 114 | 0.090 |
Why?
|
Fluorouracil | 1 | 2012 | 556 | 0.090 |
Why?
|
Biostatistics | 1 | 2010 | 20 | 0.090 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 3 | 2014 | 122 | 0.090 |
Why?
|
Models, Theoretical | 3 | 2014 | 480 | 0.090 |
Why?
|
Drug Resistance, Microbial | 4 | 2001 | 72 | 0.090 |
Why?
|
Antibody Formation | 3 | 2008 | 171 | 0.090 |
Why?
|
Genetic Heterogeneity | 2 | 2001 | 62 | 0.090 |
Why?
|
Mice, Knockout | 4 | 2019 | 1918 | 0.090 |
Why?
|
Isoantigens | 1 | 2009 | 66 | 0.090 |
Why?
|
Mathematics | 4 | 1997 | 190 | 0.090 |
Why?
|
Natural Language Processing | 2 | 2020 | 37 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2011 | 188 | 0.090 |
Why?
|
Health Promotion | 1 | 2011 | 160 | 0.090 |
Why?
|
Monoamine Oxidase | 1 | 2009 | 24 | 0.090 |
Why?
|
Social Behavior Disorders | 1 | 2009 | 19 | 0.090 |
Why?
|
DNA Probes, HLA | 1 | 1988 | 2 | 0.090 |
Why?
|
Folic Acid | 1 | 2009 | 60 | 0.090 |
Why?
|
Virus Internalization | 1 | 2009 | 39 | 0.090 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 727 | 0.090 |
Why?
|
Multivariate Analysis | 4 | 2017 | 997 | 0.080 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2008 | 43 | 0.080 |
Why?
|
Gangliosides | 1 | 2008 | 10 | 0.080 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 397 | 0.080 |
Why?
|
Genetic Phenomena | 1 | 2008 | 6 | 0.080 |
Why?
|
Genetic Privacy | 1 | 2008 | 12 | 0.080 |
Why?
|
Complex Mixtures | 1 | 2008 | 5 | 0.080 |
Why?
|
Guillain-Barre Syndrome | 1 | 2008 | 16 | 0.080 |
Why?
|
Pancreas | 1 | 2010 | 239 | 0.080 |
Why?
|
Genes, Dominant | 3 | 2014 | 117 | 0.080 |
Why?
|
Sequence Alignment | 4 | 2013 | 351 | 0.080 |
Why?
|
Penetrance | 4 | 2013 | 44 | 0.080 |
Why?
|
Microsatellite Repeats | 4 | 2002 | 141 | 0.080 |
Why?
|
Codon | 3 | 1999 | 124 | 0.080 |
Why?
|
Respiratory System | 4 | 2013 | 116 | 0.080 |
Why?
|
Neutrophils | 1 | 2009 | 306 | 0.080 |
Why?
|
HMGB2 Protein | 1 | 2008 | 4 | 0.080 |
Why?
|
Nerve Degeneration | 1 | 2008 | 83 | 0.080 |
Why?
|
Speech | 2 | 2022 | 84 | 0.080 |
Why?
|
High Mobility Group Proteins | 1 | 2008 | 26 | 0.080 |
Why?
|
Population | 1 | 2008 | 35 | 0.080 |
Why?
|
Brain Neoplasms | 1 | 2014 | 763 | 0.080 |
Why?
|
Confidentiality | 1 | 2008 | 77 | 0.080 |
Why?
|
Binding Sites | 4 | 2020 | 1098 | 0.080 |
Why?
|
Nucleocapsid Proteins | 4 | 2014 | 10 | 0.080 |
Why?
|
Molecular Chaperones | 1 | 2008 | 110 | 0.080 |
Why?
|
Indonesia | 3 | 2007 | 11 | 0.080 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 104 | 0.080 |
Why?
|
Acclimatization | 3 | 2003 | 76 | 0.080 |
Why?
|
Medical Records | 1 | 2008 | 119 | 0.080 |
Why?
|
Depressive Disorder | 1 | 1989 | 218 | 0.080 |
Why?
|
Diabetic Nephropathies | 1 | 2010 | 248 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 850 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2009 | 153 | 0.080 |
Why?
|
Amyloid beta-Peptides | 2 | 2019 | 203 | 0.080 |
Why?
|
C-Peptide | 3 | 2013 | 174 | 0.080 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2007 | 47 | 0.080 |
Why?
|
Protein Sorting Signals | 1 | 2007 | 43 | 0.080 |
Why?
|
Chromosome Segregation | 2 | 2004 | 32 | 0.080 |
Why?
|
Trans-Activators | 1 | 2010 | 429 | 0.080 |
Why?
|
Reference Standards | 3 | 2014 | 159 | 0.080 |
Why?
|
Ubiquitin | 1 | 2008 | 93 | 0.080 |
Why?
|
Coronary Stenosis | 1 | 2007 | 39 | 0.080 |
Why?
|
Morbidity | 3 | 2004 | 146 | 0.080 |
Why?
|
Spondylitis, Ankylosing | 1 | 2007 | 24 | 0.070 |
Why?
|
Prospective Studies | 4 | 2021 | 4194 | 0.070 |
Why?
|
Lysine | 1 | 2008 | 147 | 0.070 |
Why?
|
Homozygote | 2 | 2005 | 200 | 0.070 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 76 | 0.070 |
Why?
|
Thyroiditis, Autoimmune | 2 | 2020 | 16 | 0.070 |
Why?
|
Respiratory Tract Diseases | 2 | 1999 | 45 | 0.070 |
Why?
|
Oligonucleotide Probes | 1 | 2006 | 39 | 0.070 |
Why?
|
Excitatory Amino Acid Transporter 3 | 1 | 2006 | 5 | 0.070 |
Why?
|
Genetic Vectors | 3 | 2011 | 438 | 0.070 |
Why?
|
Programming Languages | 1 | 2006 | 15 | 0.070 |
Why?
|
Indians, North American | 2 | 2011 | 48 | 0.070 |
Why?
|
Monte Carlo Method | 4 | 1999 | 185 | 0.070 |
Why?
|
Reference Values | 6 | 2009 | 673 | 0.070 |
Why?
|
Data Mining | 2 | 2020 | 42 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 350 | 0.070 |
Why?
|
Abdominal Fat | 1 | 2006 | 13 | 0.070 |
Why?
|
Transfection | 4 | 2011 | 895 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 252 | 0.070 |
Why?
|
Chromosomes, Artificial, Yeast | 5 | 1996 | 37 | 0.070 |
Why?
|
Cysteine Proteinase Inhibitors | 2 | 2003 | 53 | 0.070 |
Why?
|
Coronary Angiography | 1 | 2007 | 229 | 0.070 |
Why?
|
Horse Diseases | 1 | 2005 | 1 | 0.070 |
Why?
|
Influenza A Virus, H3N8 Subtype | 1 | 2005 | 1 | 0.070 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.070 |
Why?
|
Protein Conformation | 4 | 2014 | 881 | 0.070 |
Why?
|
Species Specificity | 5 | 2005 | 678 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 1305 | 0.070 |
Why?
|
Upstream Stimulatory Factors | 1 | 2005 | 5 | 0.070 |
Why?
|
Finland | 3 | 2017 | 29 | 0.070 |
Why?
|
Protein Structure, Tertiary | 4 | 2011 | 736 | 0.070 |
Why?
|
Microarray Analysis | 2 | 2021 | 96 | 0.070 |
Why?
|
Single-Blind Method | 2 | 2008 | 151 | 0.070 |
Why?
|
Dog Diseases | 1 | 2005 | 35 | 0.070 |
Why?
|
Ethics, Medical | 1 | 2008 | 306 | 0.070 |
Why?
|
Informed Consent | 1 | 2008 | 266 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2007 | 307 | 0.070 |
Why?
|
Survival Rate | 4 | 2013 | 1856 | 0.070 |
Why?
|
Siblings | 3 | 2014 | 111 | 0.070 |
Why?
|
Pilot Projects | 2 | 2020 | 837 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2018 | 2260 | 0.070 |
Why?
|
Mitochondria | 2 | 2013 | 535 | 0.070 |
Why?
|
Reverse Genetics | 2 | 2015 | 3 | 0.070 |
Why?
|
Viral Plaque Assay | 3 | 2011 | 19 | 0.070 |
Why?
|
Sulfonylurea Receptors | 5 | 2007 | 50 | 0.060 |
Why?
|
Heterozygote | 5 | 2007 | 365 | 0.060 |
Why?
|
Serologic Tests | 2 | 2008 | 41 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 738 | 0.060 |
Why?
|
North America | 4 | 2008 | 179 | 0.060 |
Why?
|
Vietnam | 3 | 2009 | 14 | 0.060 |
Why?
|
Nigeria | 2 | 2007 | 152 | 0.060 |
Why?
|
Drug Interactions | 2 | 2021 | 248 | 0.060 |
Why?
|
Mites | 1 | 2004 | 16 | 0.060 |
Why?
|
Bronchitis | 2 | 2020 | 7 | 0.060 |
Why?
|
Chromosomes, Human, Pair 9 | 2 | 2016 | 86 | 0.060 |
Why?
|
Cost-Benefit Analysis | 5 | 2006 | 450 | 0.060 |
Why?
|
Microbial Sensitivity Tests | 3 | 2014 | 142 | 0.060 |
Why?
|
Hyperlipidemia, Familial Combined | 1 | 2003 | 5 | 0.060 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 382 | 0.060 |
Why?
|
Biology | 1 | 2024 | 50 | 0.060 |
Why?
|
Iodide Peroxidase | 2 | 1999 | 203 | 0.060 |
Why?
|
Psychotic Disorders | 2 | 2021 | 184 | 0.060 |
Why?
|
Speech Disorders | 2 | 1993 | 18 | 0.060 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2004 | 203 | 0.060 |
Why?
|
Cell Survival | 2 | 2019 | 966 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 1051 | 0.060 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2003 | 8 | 0.060 |
Why?
|
Amino Acid Oxidoreductases | 1 | 2023 | 9 | 0.060 |
Why?
|
Rhabdoviridae | 1 | 1983 | 1 | 0.060 |
Why?
|
B7 Antigens | 1 | 2023 | 5 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 589 | 0.060 |
Why?
|
Central Nervous System Sensitization | 1 | 2023 | 10 | 0.060 |
Why?
|
Ebolavirus | 1 | 1983 | 6 | 0.060 |
Why?
|
Protein Interaction Mapping | 2 | 2014 | 82 | 0.060 |
Why?
|
Clostridiales | 1 | 2023 | 17 | 0.060 |
Why?
|
Tobacco Smoking | 1 | 2023 | 25 | 0.060 |
Why?
|
Biometry | 3 | 1997 | 66 | 0.060 |
Why?
|
Tobacco Smoke Pollution | 1 | 2003 | 23 | 0.060 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2023 | 56 | 0.060 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2003 | 18 | 0.060 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2023 | 23 | 0.060 |
Why?
|
New York | 1 | 2023 | 69 | 0.060 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2003 | 22 | 0.060 |
Why?
|
Sialic Acids | 3 | 2010 | 18 | 0.060 |
Why?
|
Meat | 1 | 2003 | 26 | 0.060 |
Why?
|
RNA, Small Nuclear | 1 | 2023 | 32 | 0.060 |
Why?
|
Causality | 1 | 2023 | 81 | 0.060 |
Why?
|
Thailand | 2 | 2013 | 66 | 0.060 |
Why?
|
Warfare | 1 | 2002 | 10 | 0.060 |
Why?
|
Antihypertensive Agents | 2 | 2022 | 521 | 0.060 |
Why?
|
Sequence Analysis, Protein | 1 | 2002 | 28 | 0.050 |
Why?
|
Fatal Outcome | 2 | 2006 | 293 | 0.050 |
Why?
|
Sensation Disorders | 1 | 2022 | 23 | 0.050 |
Why?
|
Individuality | 1 | 2023 | 109 | 0.050 |
Why?
|
Epoprostenol | 1 | 2022 | 46 | 0.050 |
Why?
|
Mutant Proteins | 2 | 2014 | 94 | 0.050 |
Why?
|
Kinetics | 2 | 2012 | 1513 | 0.050 |
Why?
|
Scavenger Receptors, Class F | 1 | 2021 | 1 | 0.050 |
Why?
|
Eye Proteins | 1 | 2023 | 128 | 0.050 |
Why?
|
Familial Primary Pulmonary Hypertension | 1 | 2022 | 59 | 0.050 |
Why?
|
Employment | 1 | 2002 | 52 | 0.050 |
Why?
|
Auditory Perception | 1 | 2023 | 96 | 0.050 |
Why?
|
Recurrence | 3 | 2012 | 1137 | 0.050 |
Why?
|
Resorcinols | 1 | 2021 | 5 | 0.050 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 21 | 0.050 |
Why?
|
Fibroblast Growth Factors | 1 | 2022 | 80 | 0.050 |
Why?
|
HapMap Project | 2 | 2012 | 47 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2021 | 50 | 0.050 |
Why?
|
Perception | 1 | 2023 | 167 | 0.050 |
Why?
|
Swine Diseases | 2 | 2013 | 14 | 0.050 |
Why?
|
3' Untranslated Regions | 2 | 2012 | 92 | 0.050 |
Why?
|
Population Health | 1 | 2022 | 33 | 0.050 |
Why?
|
HN Protein | 1 | 2001 | 4 | 0.050 |
Why?
|
Hypothyroidism | 2 | 2020 | 232 | 0.050 |
Why?
|
Occupational Diseases | 1 | 2002 | 55 | 0.050 |
Why?
|
Metabolic Networks and Pathways | 1 | 2022 | 78 | 0.050 |
Why?
|
Washington | 2 | 2006 | 48 | 0.050 |
Why?
|
Genetic Counseling | 1 | 2022 | 100 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 17 | 0.050 |
Why?
|
Asia | 3 | 2008 | 94 | 0.050 |
Why?
|
Asbestos | 2 | 2011 | 22 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2014 | 1203 | 0.050 |
Why?
|
High-Throughput Screening Assays | 1 | 2022 | 55 | 0.050 |
Why?
|
Cell Nucleus | 2 | 2016 | 579 | 0.050 |
Why?
|
Leukocyte Count | 1 | 2021 | 220 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2016 | 1537 | 0.050 |
Why?
|
Unnecessary Procedures | 1 | 2021 | 51 | 0.050 |
Why?
|
False Positive Reactions | 2 | 2014 | 216 | 0.050 |
Why?
|
Cross-Cultural Comparison | 1 | 2001 | 34 | 0.050 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2000 | 25 | 0.050 |
Why?
|
Muscle Hypotonia | 1 | 2021 | 42 | 0.050 |
Why?
|
Dimaprit | 1 | 2020 | 1 | 0.050 |
Why?
|
South Dakota | 1 | 2000 | 47 | 0.050 |
Why?
|
Ships | 1 | 2000 | 5 | 0.050 |
Why?
|
Quail | 1 | 2000 | 8 | 0.050 |
Why?
|
Bird Diseases | 1 | 2000 | 7 | 0.050 |
Why?
|
Finches | 1 | 2021 | 55 | 0.050 |
Why?
|
Survivors | 1 | 2022 | 225 | 0.050 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2015 | 59 | 0.050 |
Why?
|
Immunoglobulin E | 1 | 2001 | 143 | 0.050 |
Why?
|
Family Characteristics | 1 | 2000 | 46 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2023 | 377 | 0.050 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2020 | 42 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 beta | 2 | 2012 | 37 | 0.050 |
Why?
|
Tobacco Products | 1 | 2021 | 40 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
Lipoproteins, LDL | 1 | 2020 | 83 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2023 | 347 | 0.050 |
Why?
|
Proteome | 1 | 2021 | 124 | 0.050 |
Why?
|
Administration, Oral | 1 | 2002 | 683 | 0.050 |
Why?
|
Coronaviridae Infections | 2 | 1990 | 7 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2020 | 12 | 0.050 |
Why?
|
Procollagen | 1 | 2020 | 8 | 0.050 |
Why?
|
Hemoglobins | 1 | 2020 | 179 | 0.050 |
Why?
|
Cat Diseases | 2 | 1990 | 20 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2011 | 122 | 0.050 |
Why?
|
A549 Cells | 1 | 2020 | 39 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 | 2 | 2012 | 63 | 0.050 |
Why?
|
Travel | 1 | 2000 | 68 | 0.050 |
Why?
|
Scleroderma, Systemic | 1 | 2020 | 43 | 0.050 |
Why?
|
Peritonitis | 2 | 1990 | 29 | 0.050 |
Why?
|
Crystallography, X-Ray | 2 | 2014 | 484 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2020 | 38 | 0.050 |
Why?
|
Musculoskeletal System | 1 | 2020 | 14 | 0.050 |
Why?
|
Neuropilin-1 | 1 | 2019 | 14 | 0.050 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 3087 | 0.050 |
Why?
|
Skin | 1 | 2023 | 554 | 0.050 |
Why?
|
Reye Syndrome | 1 | 1999 | 22 | 0.050 |
Why?
|
Secretory Pathway | 1 | 2020 | 22 | 0.050 |
Why?
|
Chondrocytes | 1 | 2020 | 60 | 0.050 |
Why?
|
Artifacts | 1 | 2001 | 244 | 0.050 |
Why?
|
Africa | 3 | 2007 | 98 | 0.050 |
Why?
|
Loneliness | 1 | 2019 | 24 | 0.040 |
Why?
|
Health Priorities | 1 | 1999 | 23 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 859 | 0.040 |
Why?
|
Pregnancy Outcome | 2 | 2012 | 247 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2004 | 724 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 1999 | 136 | 0.040 |
Why?
|
Incidence | 3 | 2017 | 1568 | 0.040 |
Why?
|
Paraffin Embedding | 2 | 2014 | 78 | 0.040 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 135 | 0.040 |
Why?
|
Chronic Disease | 1 | 2023 | 968 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 362 | 0.040 |
Why?
|
Capital Financing | 1 | 1999 | 4 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2020 | 217 | 0.040 |
Why?
|
DNA, Satellite | 2 | 1995 | 18 | 0.040 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 1996 | 135 | 0.040 |
Why?
|
RNA Interference | 1 | 2020 | 368 | 0.040 |
Why?
|
Neovascularization, Physiologic | 1 | 2019 | 132 | 0.040 |
Why?
|
Gene Editing | 1 | 2019 | 42 | 0.040 |
Why?
|
Syndrome | 1 | 2020 | 446 | 0.040 |
Why?
|
Military Personnel | 1 | 2020 | 85 | 0.040 |
Why?
|
Parents | 3 | 2012 | 269 | 0.040 |
Why?
|
Disease Management | 1 | 2021 | 327 | 0.040 |
Why?
|
Restriction Mapping | 2 | 1996 | 157 | 0.040 |
Why?
|
Genes, Reporter | 2 | 2012 | 266 | 0.040 |
Why?
|
Health Services | 1 | 1999 | 55 | 0.040 |
Why?
|
Dexamethasone | 1 | 2020 | 326 | 0.040 |
Why?
|
Down-Regulation | 1 | 2020 | 504 | 0.040 |
Why?
|
Pneumonia | 2 | 2014 | 178 | 0.040 |
Why?
|
Angiotensin II | 1 | 2018 | 94 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 2 | 2011 | 73 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2019 | 121 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2020 | 231 | 0.040 |
Why?
|
Sequestosome-1 Protein | 2 | 2008 | 22 | 0.040 |
Why?
|
Mass Spectrometry | 2 | 2009 | 188 | 0.040 |
Why?
|
Osteogenesis | 1 | 2020 | 241 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 877 | 0.040 |
Why?
|
Opportunistic Infections | 1 | 1998 | 59 | 0.040 |
Why?
|
Body Weight | 2 | 2014 | 459 | 0.040 |
Why?
|
HIV-1 | 1 | 1999 | 163 | 0.040 |
Why?
|
Nursing Homes | 2 | 2000 | 109 | 0.040 |
Why?
|
DNA, Complementary | 2 | 1996 | 393 | 0.040 |
Why?
|
Urethritis | 1 | 2017 | 2 | 0.040 |
Why?
|
Kidney | 3 | 2016 | 1240 | 0.040 |
Why?
|
Inventions | 1 | 2017 | 13 | 0.040 |
Why?
|
Cystitis | 1 | 2017 | 13 | 0.040 |
Why?
|
Health Expenditures | 1 | 1999 | 86 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2018 | 129 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2019 | 160 | 0.040 |
Why?
|
Poland | 1 | 1997 | 17 | 0.040 |
Why?
|
Marriage | 1 | 1997 | 26 | 0.040 |
Why?
|
Inpatients | 1 | 2020 | 295 | 0.040 |
Why?
|
Child Language | 1 | 1997 | 5 | 0.040 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2017 | 14 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 429 | 0.040 |
Why?
|
Self Report | 1 | 2019 | 287 | 0.040 |
Why?
|
Nucleotide Motifs | 1 | 2017 | 47 | 0.040 |
Why?
|
Contraindications | 2 | 2010 | 71 | 0.040 |
Why?
|
Human Genome Project | 1 | 2017 | 19 | 0.040 |
Why?
|
Asia, Southeastern | 2 | 2008 | 16 | 0.040 |
Why?
|
Research Report | 1 | 2017 | 44 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 1997 | 153 | 0.040 |
Why?
|
Markov Chains | 1 | 1997 | 125 | 0.040 |
Why?
|
Migraine Disorders | 1 | 2017 | 40 | 0.040 |
Why?
|
Homeobox Protein Nkx-2.5 | 1 | 2016 | 12 | 0.040 |
Why?
|
Apolipoprotein C-III | 1 | 1996 | 8 | 0.040 |
Why?
|
Apolipoproteins A | 1 | 1996 | 11 | 0.040 |
Why?
|
Financial Management | 1 | 1997 | 21 | 0.040 |
Why?
|
Matched-Pair Analysis | 3 | 2002 | 43 | 0.040 |
Why?
|
Drug Resistance | 1 | 2018 | 256 | 0.040 |
Why?
|
Military Medicine | 1 | 1997 | 20 | 0.040 |
Why?
|
Irritable Bowel Syndrome | 1 | 2017 | 45 | 0.040 |
Why?
|
Haploidy | 1 | 1996 | 31 | 0.040 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 25 | 0.040 |
Why?
|
NAV1.5 Voltage-Gated Sodium Channel | 1 | 2016 | 31 | 0.040 |
Why?
|
Behavior, Animal | 1 | 2020 | 373 | 0.040 |
Why?
|
Pulse Wave Analysis | 1 | 2016 | 10 | 0.040 |
Why?
|
Amyloidosis | 1 | 2018 | 115 | 0.040 |
Why?
|
Italy | 1 | 1996 | 106 | 0.040 |
Why?
|
Trinucleotide Repeats | 1 | 1996 | 31 | 0.040 |
Why?
|
Nucleotide Mapping | 3 | 1994 | 7 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 2 | 1993 | 126 | 0.040 |
Why?
|
Seroepidemiologic Studies | 3 | 2002 | 55 | 0.040 |
Why?
|
Patient Admission | 1 | 1997 | 112 | 0.040 |
Why?
|
Vascular Stiffness | 1 | 2016 | 26 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 916 | 0.040 |
Why?
|
tRNA Methyltransferases | 1 | 2016 | 12 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.040 |
Why?
|
Glycogen Synthase | 1 | 1996 | 22 | 0.040 |
Why?
|
KCNQ1 Potassium Channel | 1 | 2016 | 16 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 1996 | 71 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2018 | 460 | 0.040 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1994 | 416 | 0.040 |
Why?
|
Pyrrolidinones | 1 | 2016 | 16 | 0.040 |
Why?
|
Interviews as Topic | 2 | 2011 | 319 | 0.040 |
Why?
|
Immune Evasion | 1 | 2016 | 33 | 0.040 |
Why?
|
Denmark | 1 | 1995 | 15 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 1987 | 0.030 |
Why?
|
Organizational Case Studies | 2 | 2011 | 27 | 0.030 |
Why?
|
Serial Passage | 1 | 2015 | 3 | 0.030 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2016 | 45 | 0.030 |
Why?
|
Models, Animal | 1 | 2017 | 261 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 48 | 0.030 |
Why?
|
Thimerosal | 2 | 2006 | 6 | 0.030 |
Why?
|
Preservatives, Pharmaceutical | 2 | 2006 | 10 | 0.030 |
Why?
|
Amyloid | 1 | 1996 | 85 | 0.030 |
Why?
|
Cancer Survivors | 1 | 2017 | 85 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 86 | 0.030 |
Why?
|
Community Health Centers | 1 | 1997 | 113 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2012 | 857 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 1996 | 157 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 104 | 0.030 |
Why?
|
Macular Degeneration | 1 | 1996 | 58 | 0.030 |
Why?
|
Allantois | 1 | 1995 | 3 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1995 | 54 | 0.030 |
Why?
|
Phylogeography | 1 | 2015 | 41 | 0.030 |
Why?
|
Enteral Nutrition | 1 | 1995 | 102 | 0.030 |
Why?
|
Receptors, Glucagon | 1 | 2015 | 11 | 0.030 |
Why?
|
Glycemic Index | 1 | 2015 | 10 | 0.030 |
Why?
|
Gastrostomy | 1 | 1995 | 69 | 0.030 |
Why?
|
Ovum | 1 | 2015 | 58 | 0.030 |
Why?
|
Dioxygenases | 1 | 2015 | 74 | 0.030 |
Why?
|
Hyperthyroxinemia | 1 | 1995 | 17 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 234 | 0.030 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 35 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
Heart Atria | 1 | 2016 | 245 | 0.030 |
Why?
|
Web Browser | 1 | 2014 | 5 | 0.030 |
Why?
|
Cambodia | 1 | 2014 | 5 | 0.030 |
Why?
|
Formaldehyde | 1 | 2014 | 52 | 0.030 |
Why?
|
Consensus Sequence | 1 | 2014 | 64 | 0.030 |
Why?
|
Antibody Specificity | 1 | 1995 | 129 | 0.030 |
Why?
|
Netrins | 1 | 2014 | 4 | 0.030 |
Why?
|
Sequence Homology | 1 | 1994 | 28 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 1995 | 142 | 0.030 |
Why?
|
Peroxisome-Targeting Signal 1 Receptor | 1 | 2014 | 3 | 0.030 |
Why?
|
Mouth Mucosa | 1 | 2014 | 66 | 0.030 |
Why?
|
Microsomes, Liver | 1 | 2014 | 49 | 0.030 |
Why?
|
Indazoles | 1 | 2014 | 68 | 0.030 |
Why?
|
Datasets as Topic | 1 | 2014 | 71 | 0.030 |
Why?
|
Budesonide | 1 | 2014 | 44 | 0.030 |
Why?
|
Serum Albumin | 1 | 1995 | 130 | 0.030 |
Why?
|
Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
Basal Metabolism | 1 | 2014 | 20 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2014 | 83 | 0.030 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2015 | 148 | 0.030 |
Why?
|
Animal Structures | 1 | 2014 | 22 | 0.030 |
Why?
|
Protective Agents | 1 | 2014 | 32 | 0.030 |
Why?
|
Chromatography, Gel | 1 | 2014 | 103 | 0.030 |
Why?
|
Deglutition Disorders | 1 | 1995 | 115 | 0.030 |
Why?
|
Thinness | 1 | 2014 | 43 | 0.030 |
Why?
|
Gene Deletion | 2 | 2008 | 328 | 0.030 |
Why?
|
Sex Distribution | 2 | 2009 | 173 | 0.030 |
Why?
|
Twins, Monozygotic | 1 | 2014 | 57 | 0.030 |
Why?
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2014 | 41 | 0.030 |
Why?
|
Poisson Distribution | 2 | 2004 | 51 | 0.030 |
Why?
|
Protein Stability | 1 | 2014 | 99 | 0.030 |
Why?
|
Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2014 | 80 | 0.030 |
Why?
|
Speech Production Measurement | 1 | 1993 | 9 | 0.030 |
Why?
|
Diagnosis | 1 | 2013 | 14 | 0.030 |
Why?
|
Hypothalamus | 1 | 2014 | 79 | 0.030 |
Why?
|
Cell Count | 1 | 2014 | 194 | 0.030 |
Why?
|
Simvastatin | 1 | 2014 | 106 | 0.030 |
Why?
|
Pharmacokinetics | 1 | 2013 | 12 | 0.030 |
Why?
|
Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2013 | 2 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 1994 | 56 | 0.030 |
Why?
|
Contact Tracing | 1 | 2013 | 29 | 0.030 |
Why?
|
Caribbean Region | 1 | 2013 | 20 | 0.030 |
Why?
|
Electroencephalography | 1 | 2017 | 707 | 0.030 |
Why?
|
Forecasting | 2 | 2008 | 303 | 0.030 |
Why?
|
bcl-2-Associated X Protein | 1 | 2013 | 47 | 0.030 |
Why?
|
Placebos | 1 | 1993 | 218 | 0.030 |
Why?
|
Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1993 | 8 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2014 | 299 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 138 | 0.030 |
Why?
|
Bacterial Proteins | 2 | 1991 | 861 | 0.030 |
Why?
|
Receptor, ErbB-2 | 1 | 2014 | 223 | 0.030 |
Why?
|
Multilocus Sequence Typing | 1 | 2013 | 11 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2008 | 378 | 0.030 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.030 |
Why?
|
Publishing | 1 | 2014 | 90 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2014 | 280 | 0.030 |
Why?
|
Respiratory Therapy | 1 | 1993 | 14 | 0.030 |
Why?
|
RNA Isoforms | 1 | 2012 | 5 | 0.030 |
Why?
|
Viral Envelope Proteins | 1 | 1993 | 94 | 0.030 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 216 | 0.030 |
Why?
|
Skin Tests | 2 | 2004 | 44 | 0.030 |
Why?
|
Glycogen Phosphorylase | 1 | 2012 | 6 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2013 | 155 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 272 | 0.030 |
Why?
|
SAP90-PSD95 Associated Proteins | 1 | 2012 | 2 | 0.030 |
Why?
|
Chicago | 2 | 2013 | 1377 | 0.030 |
Why?
|
Biotransformation | 1 | 2012 | 50 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2014 | 493 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2012 | 43 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2013 | 116 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 486 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 228 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 1995 | 1014 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2014 | 172 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2014 | 418 | 0.030 |
Why?
|
Thromboembolism | 1 | 2013 | 119 | 0.030 |
Why?
|
NADP | 2 | 2003 | 45 | 0.030 |
Why?
|
Data Collection | 2 | 1997 | 371 | 0.030 |
Why?
|
Receptors, Adiponectin | 1 | 2012 | 4 | 0.030 |
Why?
|
Guatemala | 1 | 2012 | 4 | 0.030 |
Why?
|
Resistin | 1 | 2012 | 14 | 0.030 |
Why?
|
Exercise Therapy | 1 | 1993 | 78 | 0.030 |
Why?
|
Receptors, Leptin | 1 | 2012 | 32 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
Rabbits | 1 | 1993 | 636 | 0.030 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 1992 | 9 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2012 | 85 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2012 | 74 | 0.030 |
Why?
|
Students | 1 | 2013 | 146 | 0.030 |
Why?
|
Bronchial Hyperreactivity | 2 | 2004 | 77 | 0.030 |
Why?
|
Uveal Neoplasms | 1 | 2011 | 11 | 0.030 |
Why?
|
Random Allocation | 1 | 2012 | 332 | 0.030 |
Why?
|
Southwestern United States | 1 | 2011 | 8 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2012 | 130 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 162 | 0.030 |
Why?
|
Deoxycytidine Kinase | 1 | 2011 | 4 | 0.030 |
Why?
|
Virus Physiological Phenomena | 1 | 2011 | 8 | 0.030 |
Why?
|
Virginia | 1 | 2011 | 16 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2011 | 48 | 0.030 |
Why?
|
Cytogenetics | 1 | 2011 | 27 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2011 | 51 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2011 | 57 | 0.030 |
Why?
|
Epidemiologic Methods | 2 | 1989 | 59 | 0.030 |
Why?
|
Heart Ventricles | 1 | 2016 | 760 | 0.030 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1991 | 47 | 0.020 |
Why?
|
Carcinogens, Environmental | 1 | 2011 | 5 | 0.020 |
Why?
|
Radiation Effects | 1 | 2011 | 28 | 0.020 |
Why?
|
Zeolites | 1 | 2011 | 4 | 0.020 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2012 | 102 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 2011 | 12 | 0.020 |
Why?
|
Geography | 1 | 2012 | 223 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2014 | 1015 | 0.020 |
Why?
|
Methylation | 1 | 2012 | 251 | 0.020 |
Why?
|
Health Status | 2 | 2005 | 360 | 0.020 |
Why?
|
Genes, X-Linked | 1 | 2011 | 37 | 0.020 |
Why?
|
Diet | 1 | 2014 | 442 | 0.020 |
Why?
|
Micronucleus, Germline | 1 | 2010 | 3 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2012 | 255 | 0.020 |
Why?
|
Immunization Programs | 1 | 2010 | 23 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 722 | 0.020 |
Why?
|
Interpersonal Relations | 2 | 2004 | 170 | 0.020 |
Why?
|
Nutritional Status | 1 | 2011 | 83 | 0.020 |
Why?
|
Platelet Aggregation | 1 | 1990 | 44 | 0.020 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2010 | 29 | 0.020 |
Why?
|
Disability Evaluation | 2 | 2002 | 136 | 0.020 |
Why?
|
Viruses | 1 | 2011 | 78 | 0.020 |
Why?
|
HIV Infections | 1 | 1999 | 768 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 425 | 0.020 |
Why?
|
Plasmids | 1 | 2011 | 287 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 256 | 0.020 |
Why?
|
Antithrombin III | 1 | 1989 | 9 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2014 | 307 | 0.020 |
Why?
|
Perilipin-1 | 1 | 2009 | 7 | 0.020 |
Why?
|
Cerebellum | 1 | 2012 | 247 | 0.020 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1989 | 27 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 692 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2010 | 51 | 0.020 |
Why?
|
Choice Behavior | 1 | 2011 | 160 | 0.020 |
Why?
|
Thermodynamics | 1 | 2010 | 308 | 0.020 |
Why?
|
Arginine | 1 | 2009 | 136 | 0.020 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 53 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2010 | 140 | 0.020 |
Why?
|
Primary Prevention | 1 | 2010 | 85 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2001 | 165 | 0.020 |
Why?
|
Infant, Newborn, Diseases | 1 | 2010 | 111 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2010 | 128 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2009 | 152 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 386 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 1990 | 177 | 0.020 |
Why?
|
Minisatellite Repeats | 2 | 2002 | 24 | 0.020 |
Why?
|
Apolipoproteins | 1 | 1989 | 38 | 0.020 |
Why?
|
Topography, Medical | 1 | 2008 | 3 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 371 | 0.020 |
Why?
|
Apolipoproteins B | 1 | 1988 | 38 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2014 | 620 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 4 | 2 | 2000 | 30 | 0.020 |
Why?
|
Peptides | 2 | 2011 | 639 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2009 | 99 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 1990 | 408 | 0.020 |
Why?
|
Peptide Library | 1 | 2009 | 84 | 0.020 |
Why?
|
Carbohydrate Metabolism | 1 | 1988 | 30 | 0.020 |
Why?
|
Gangliosidosis, GM1 | 1 | 2008 | 2 | 0.020 |
Why?
|
Porcine Reproductive and Respiratory Syndrome | 1 | 2008 | 2 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1988 | 245 | 0.020 |
Why?
|
Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2000 | 54 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 1989 | 156 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2008 | 14 | 0.020 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2008 | 27 | 0.020 |
Why?
|
Oceania | 1 | 2008 | 4 | 0.020 |
Why?
|
Epoxide Hydrolases | 1 | 2008 | 7 | 0.020 |
Why?
|
Glycolipids | 1 | 2008 | 29 | 0.020 |
Why?
|
Neurofibrillary Tangles | 1 | 2008 | 45 | 0.020 |
Why?
|
Color Perception | 1 | 1990 | 117 | 0.020 |
Why?
|
Isotopes | 1 | 2008 | 26 | 0.020 |
Why?
|
Vaccinia virus | 1 | 1988 | 19 | 0.020 |
Why?
|
Cause of Death | 2 | 2003 | 277 | 0.020 |
Why?
|
Spleen | 1 | 2009 | 430 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 74 | 0.020 |
Why?
|
South America | 1 | 2008 | 29 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 683 | 0.020 |
Why?
|
Cell Movement | 1 | 2012 | 756 | 0.020 |
Why?
|
Deubiquitinating Enzyme CYLD | 1 | 2008 | 2 | 0.020 |
Why?
|
TNF Receptor-Associated Factor 6 | 1 | 2008 | 6 | 0.020 |
Why?
|
Polyubiquitin | 1 | 2008 | 8 | 0.020 |
Why?
|
Sulfurtransferases | 1 | 1988 | 6 | 0.020 |
Why?
|
Receptor, trkA | 1 | 2008 | 14 | 0.020 |
Why?
|
Wisconsin | 1 | 2008 | 39 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 113 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2009 | 106 | 0.020 |
Why?
|
Solubility | 1 | 2008 | 177 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 2008 | 370 | 0.020 |
Why?
|
HeLa Cells | 1 | 2009 | 498 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 893 | 0.020 |
Why?
|
Cysteine Endopeptidases | 1 | 2008 | 87 | 0.020 |
Why?
|
Oxazines | 1 | 2007 | 13 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2008 | 99 | 0.020 |
Why?
|
Receptors, Cytokine | 1 | 2007 | 28 | 0.020 |
Why?
|
Xanthenes | 1 | 2007 | 23 | 0.020 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 23 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2008 | 236 | 0.020 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 22 | 0.020 |
Why?
|
Calcium | 2 | 2003 | 1148 | 0.020 |
Why?
|
Gene Amplification | 1 | 2007 | 131 | 0.020 |
Why?
|
Blood Platelets | 1 | 1988 | 149 | 0.020 |
Why?
|
Wnt Proteins | 1 | 2008 | 123 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2010 | 324 | 0.020 |
Why?
|
Kazakhstan | 1 | 2007 | 1 | 0.020 |
Why?
|
Galactose | 1 | 2007 | 32 | 0.020 |
Why?
|
International Agencies | 1 | 2007 | 34 | 0.020 |
Why?
|
Glycoconjugates | 1 | 2007 | 10 | 0.020 |
Why?
|
Oncogenes | 1 | 2007 | 88 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1 | 2 | 1996 | 30 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 2 | 1996 | 34 | 0.020 |
Why?
|
Adherens Junctions | 1 | 2007 | 34 | 0.020 |
Why?
|
Antigens | 1 | 1988 | 228 | 0.020 |
Why?
|
Proinsulin | 1 | 2007 | 124 | 0.020 |
Why?
|
Protein Precursors | 1 | 2007 | 143 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2006 | 62 | 0.020 |
Why?
|
Exercise | 1 | 2010 | 315 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2009 | 377 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 2 | 1996 | 80 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 1987 | 177 | 0.020 |
Why?
|
Nose | 1 | 2007 | 94 | 0.020 |
Why?
|
Potassium Channels, Voltage-Gated | 1 | 2007 | 122 | 0.020 |
Why?
|
Neuregulin-1 | 1 | 2006 | 13 | 0.020 |
Why?
|
Sequence Analysis | 1 | 2006 | 26 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.020 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2005 | 7 | 0.020 |
Why?
|
Intestines | 1 | 2009 | 407 | 0.020 |
Why?
|
Biological Assay | 1 | 2006 | 78 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 268 | 0.020 |
Why?
|
Horses | 1 | 2005 | 35 | 0.020 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2005 | 72 | 0.020 |
Why?
|
Trypsin | 1 | 2005 | 95 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2008 | 306 | 0.020 |
Why?
|
Florida | 1 | 2005 | 54 | 0.020 |
Why?
|
Patient Selection | 1 | 2009 | 685 | 0.020 |
Why?
|
Luciferases | 1 | 2005 | 118 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2012 | 1456 | 0.020 |
Why?
|
Protein Folding | 1 | 2007 | 280 | 0.020 |
Why?
|
Genetic Engineering | 1 | 1986 | 114 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 2000 | 303 | 0.020 |
Why?
|
Rh-Hr Blood-Group System | 1 | 1985 | 6 | 0.020 |
Why?
|
Color Vision Defects | 1 | 1985 | 22 | 0.020 |
Why?
|
Patient Compliance | 1 | 2006 | 226 | 0.020 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1073 | 0.020 |
Why?
|
Dystonia Musculorum Deformans | 1 | 1984 | 1 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 1996 | 348 | 0.020 |
Why?
|
HLA-G Antigens | 1 | 2004 | 52 | 0.020 |
Why?
|
National Institute of Mental Health (U.S.) | 1 | 2004 | 22 | 0.020 |
Why?
|
Antigens, Dermatophagoides | 1 | 2004 | 11 | 0.020 |
Why?
|
Gene Library | 2 | 1996 | 130 | 0.020 |
Why?
|
Cricetinae | 2 | 1995 | 560 | 0.020 |
Why?
|
Adenosine Triphosphate | 2 | 1996 | 314 | 0.020 |
Why?
|
X Chromosome | 1 | 1985 | 152 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2004 | 69 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2004 | 27 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2005 | 181 | 0.020 |
Why?
|
Testosterone | 1 | 2005 | 268 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2006 | 332 | 0.020 |
Why?
|
Primates | 1 | 2005 | 151 | 0.010 |
Why?
|
Fear | 1 | 2004 | 78 | 0.010 |
Why?
|
Oropharynx | 1 | 2003 | 15 | 0.010 |
Why?
|
Hyperlipoproteinemias | 1 | 2003 | 7 | 0.010 |
Why?
|
Speech Therapy | 1 | 1983 | 8 | 0.010 |
Why?
|
Lithium | 1 | 1983 | 59 | 0.010 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 1983 | 3 | 0.010 |
Why?
|
Mammals | 1 | 2005 | 227 | 0.010 |
Why?
|
Democratic Republic of the Congo | 1 | 1983 | 5 | 0.010 |
Why?
|
Sudan | 1 | 1983 | 13 | 0.010 |
Why?
|
Epitopes | 2 | 1999 | 255 | 0.010 |
Why?
|
Dipeptides | 1 | 2003 | 46 | 0.010 |
Why?
|
Scandinavian and Nordic Countries | 1 | 2002 | 10 | 0.010 |
Why?
|
Control Groups | 1 | 2002 | 15 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2003 | 121 | 0.010 |
Why?
|
Mood Disorders | 1 | 1983 | 81 | 0.010 |
Why?
|
Cell Separation | 1 | 2003 | 196 | 0.010 |
Why?
|
DNA, Recombinant | 2 | 1996 | 67 | 0.010 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2003 | 79 | 0.010 |
Why?
|
Computer Graphics | 1 | 2003 | 100 | 0.010 |
Why?
|
Zanamivir | 1 | 2002 | 2 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 502 | 0.010 |
Why?
|
Pyrans | 1 | 2002 | 10 | 0.010 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2002 | 55 | 0.010 |
Why?
|
Guanidines | 1 | 2002 | 31 | 0.010 |
Why?
|
Acetamides | 1 | 2002 | 26 | 0.010 |
Why?
|
England | 1 | 2002 | 41 | 0.010 |
Why?
|
Ireland | 1 | 2002 | 9 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2003 | 373 | 0.010 |
Why?
|
Body Constitution | 1 | 2002 | 26 | 0.010 |
Why?
|
Haplorhini | 1 | 2002 | 81 | 0.010 |
Why?
|
Social Support | 1 | 2004 | 193 | 0.010 |
Why?
|
Infection Control | 1 | 2003 | 115 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2002 | 51 | 0.010 |
Why?
|
Deoxyglucose | 1 | 2001 | 37 | 0.010 |
Why?
|
Patient Discharge | 1 | 2004 | 296 | 0.010 |
Why?
|
Anxiety | 1 | 2004 | 287 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 2001 | 181 | 0.010 |
Why?
|
Electric Conductivity | 1 | 2001 | 144 | 0.010 |
Why?
|
Cross Infection | 1 | 2003 | 141 | 0.010 |
Why?
|
Intracellular Membranes | 1 | 2001 | 117 | 0.010 |
Why?
|
Thyroxine | 2 | 1995 | 344 | 0.010 |
Why?
|
Length of Stay | 1 | 2004 | 697 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2002 | 80 | 0.010 |
Why?
|
DNA Replication | 1 | 2002 | 164 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2003 | 271 | 0.010 |
Why?
|
Disabled Persons | 1 | 2002 | 67 | 0.010 |
Why?
|
Untranslated Regions | 1 | 2000 | 19 | 0.010 |
Why?
|
Arizona | 1 | 2000 | 10 | 0.010 |
Why?
|
Vaccines, Combined | 1 | 2000 | 4 | 0.010 |
Why?
|
Immunoglobulin A, Secretory | 1 | 2000 | 18 | 0.010 |
Why?
|
Sick Leave | 1 | 2000 | 13 | 0.010 |
Why?
|
Selection Bias | 1 | 2000 | 37 | 0.010 |
Why?
|
Mass Vaccination | 1 | 2000 | 8 | 0.010 |
Why?
|
Oligopeptides | 1 | 2001 | 179 | 0.010 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2000 | 5 | 0.010 |
Why?
|
Neuropeptides | 1 | 2000 | 112 | 0.010 |
Why?
|
Adipocytes | 1 | 2001 | 155 | 0.010 |
Why?
|
Specific Pathogen-Free Organisms | 2 | 1990 | 74 | 0.010 |
Why?
|
Emotions | 1 | 2004 | 340 | 0.010 |
Why?
|
Acute Disease | 2 | 1994 | 824 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2000 | 307 | 0.010 |
Why?
|
Carrier State | 1 | 2000 | 39 | 0.010 |
Why?
|
Cats | 2 | 1990 | 303 | 0.010 |
Why?
|
Health Surveys | 1 | 2000 | 238 | 0.010 |
Why?
|
Goiter | 1 | 1999 | 43 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 1999 | 66 | 0.010 |
Why?
|
Viremia | 1 | 1999 | 54 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2004 | 610 | 0.010 |
Why?
|
Congenital Hypothyroidism | 1 | 1999 | 79 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1999 | 180 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 376 | 0.010 |
Why?
|
Speech-Language Pathology | 1 | 1997 | 4 | 0.010 |
Why?
|
Blotting, Western | 1 | 1999 | 781 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1997 | 154 | 0.010 |
Why?
|
Transportation | 1 | 1997 | 18 | 0.010 |
Why?
|
Fees and Charges | 1 | 1997 | 14 | 0.010 |
Why?
|
Economic Competition | 1 | 1997 | 12 | 0.010 |
Why?
|
Lung Diseases, Interstitial | 1 | 2000 | 234 | 0.010 |
Why?
|
Health Care Costs | 1 | 1999 | 237 | 0.010 |
Why?
|
Income | 1 | 1997 | 75 | 0.010 |
Why?
|
Efficiency, Organizational | 1 | 1997 | 58 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 1999 | 149 | 0.010 |
Why?
|
Sequence Tagged Sites | 1 | 1996 | 11 | 0.010 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1996 | 49 | 0.010 |
Why?
|
Islet Amyloid Polypeptide | 1 | 1996 | 25 | 0.010 |
Why?
|
Hemiplegia | 1 | 1995 | 15 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2000 | 1822 | 0.010 |
Why?
|
Leukemia | 1 | 1998 | 318 | 0.010 |
Why?
|
Health Care Surveys | 1 | 1997 | 277 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1995 | 72 | 0.010 |
Why?
|
Receptors, Glucocorticoid | 1 | 1996 | 117 | 0.010 |
Why?
|
Mice, Obese | 1 | 1995 | 44 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 1997 | 174 | 0.010 |
Why?
|
Sulfonylurea Compounds | 1 | 1995 | 64 | 0.010 |
Why?
|
Jews | 1 | 1995 | 42 | 0.010 |
Why?
|
Genes, Recessive | 1 | 1995 | 87 | 0.010 |
Why?
|
Triiodothyronine, Reverse | 1 | 1995 | 32 | 0.010 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 1995 | 35 | 0.010 |
Why?
|
Molecular Probes | 1 | 1995 | 35 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1995 | 290 | 0.010 |
Why?
|
Maryland | 1 | 1994 | 35 | 0.010 |
Why?
|
Geriatric Assessment | 1 | 1995 | 166 | 0.010 |
Why?
|
Hemagglutination, Viral | 2 | 1984 | 4 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1994 | 173 | 0.010 |
Why?
|
Medicaid | 1 | 1997 | 216 | 0.010 |
Why?
|
Respiratory Distress Syndrome, Newborn | 1 | 1994 | 53 | 0.010 |
Why?
|
Dyslexia | 1 | 1993 | 11 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1995 | 1040 | 0.010 |
Why?
|
Ion Channel Gating | 1 | 1996 | 323 | 0.010 |
Why?
|
Genomic Library | 1 | 1993 | 33 | 0.010 |
Why?
|
Chromosome Banding | 1 | 1993 | 74 | 0.010 |
Why?
|
Karyotyping | 1 | 1993 | 250 | 0.010 |
Why?
|
Cytosol | 1 | 1993 | 189 | 0.010 |
Why?
|
Hemagglutination Tests | 1 | 1991 | 11 | 0.010 |
Why?
|
Iodides | 1 | 1991 | 18 | 0.010 |
Why?
|
Thyrotropin-Releasing Hormone | 1 | 1991 | 40 | 0.010 |
Why?
|
Autoradiography | 1 | 1990 | 69 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1990 | 274 | 0.010 |
Why?
|
Adenosine Diphosphate | 1 | 1990 | 55 | 0.010 |
Why?
|
Epinephrine | 1 | 1990 | 84 | 0.010 |
Why?
|
Photometry | 1 | 1990 | 14 | 0.010 |
Why?
|
Vision Tests | 1 | 1990 | 20 | 0.010 |
Why?
|
Thrombin Time | 1 | 1989 | 4 | 0.010 |
Why?
|
Prothrombin Time | 1 | 1989 | 20 | 0.010 |
Why?
|
Partial Thromboplastin Time | 1 | 1989 | 18 | 0.010 |
Why?
|
Thyrotropin | 1 | 1991 | 280 | 0.010 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 1989 | 28 | 0.010 |
Why?
|
Fibrinogen | 1 | 1989 | 56 | 0.010 |
Why?
|
Platelet Count | 1 | 1989 | 92 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1991 | 270 | 0.010 |
Why?
|
Triiodothyronine | 1 | 1991 | 339 | 0.010 |
Why?
|
Collagen | 1 | 1990 | 268 | 0.010 |
Why?
|
Light | 1 | 1990 | 289 | 0.010 |
Why?
|
Immunochemistry | 1 | 1988 | 16 | 0.010 |
Why?
|
Arylsulfotransferase | 1 | 1988 | 4 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1988 | 314 | 0.000 |
Why?
|
Pennsylvania | 1 | 1986 | 75 | 0.000 |
Why?
|
Apomorphine | 1 | 1984 | 10 | 0.000 |
Why?
|
Rats, Mutant Strains | 1 | 1984 | 23 | 0.000 |
Why?
|
Haloperidol | 1 | 1984 | 30 | 0.000 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1984 | 17 | 0.000 |
Why?
|
Brain Chemistry | 1 | 1984 | 121 | 0.000 |
Why?
|
Norepinephrine | 1 | 1984 | 167 | 0.000 |
Why?
|
Hospitals, Psychiatric | 1 | 1983 | 22 | 0.000 |
Why?
|
Dopamine | 1 | 1984 | 275 | 0.000 |
Why?
|
Erythrocytes | 1 | 1983 | 255 | 0.000 |
Why?
|
Motor Activity | 1 | 1984 | 327 | 0.000 |
Why?
|
Antigens, Surface | 1 | 1980 | 101 | 0.000 |
Why?
|
Adaptation, Biological | 1 | 1977 | 85 | 0.000 |
Why?
|